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Abstract
Dengue is the most important arboviral disease affecting humans. Although mortality 
is generally low, dengue generates a significant burden for health services in endemic 
countries. Pathogenesis is poorly understood. Secondary dengue is one important risk 
factor for severe disease, but current algorithms to differentiate primary from 
secondary infections are of limited utility. Viral burden is also thought to be a major 
factor influencing disease severity, but existing knowledge of the magnitude and 
kinetics of plasma viremia in association with different dengue serotypes, primary 
versus secondary immune status, and/or clinical markers of disease severity, is limited 
and inconsistent.
I first set out to establish novel algorithms that permit differentiation of primary from 
secondary dengue at any day of illness with high accuracy. Using serial samples from 
249 well-characterized patients, categorized as having primary or secondary 
infections on the basis of PRNTs after six months, I developed a number of models; 
the algorithm based on the Panbio Indirect IgG performed best (accuracy, 85%), 
although the models based on the in-house IgG and in-house IgM/IgG ratio were also 
good (accuracy, 84%). I subsequently applied the IgM/IgG ratio algorithm to define 
the immune status of 884 patients previously enrolled into early dengue studies. Using 
serial daily plasma samples I describe detailed plasma viremia responses for 581 
DENV1, 152 DENV2 and 151 DENV3 infections. In general DENV1 infections 
resulted in higher plasma viremia than did DENV2 or DENV3 infections. Overall 
viremia was higher in primary than secondary DENVI and DENV3 infections, 
although similar in DENV2 primary and secondary infections. In addition, higher 
viremia on Day3 of illness was significantly associated with several disease severity 
markers: lower platelet nadir, higher haemoconcentration and an increased risk of 
developing shock and bleeding.
Finally I evaluated the effect of early prednisolone therapy on plasma viremia and 
immune responses, using serial samples from a clinical trial assessing the safety of 
early oral corticosteroid therapy. Prednisolone did not augment plasma viremia or 
NS1 antigenaemia, confirming the safety of using the drug during active viral 
replication. However, the effects of the drug on a range of immune correlates was also 
limited, consistent with prednisolone having negligible measurable benefits in the 
clinical trial on which this work was based.
Authorship
The work presented here was done primarily by me, but with contributions from some 
other people as described below. My supervisors provided extensive training and 
supervision throughout the time I did my PhD program.
For most of my laboratory studies I used plasma samples and clinical information 
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I carried out all the laboratory work presented in this thesis with the following 
exceptions: 1) The PRNT assays (Chapter 3) were done at the laboratory of Dr Steve 
Whitehead, at the National Institute of Allergy and Infectious Diseases, NIH, USA. 2) 
Approximately 20% of the RT-PCR reactions on the daily specimens for the work 
described in Chapter 4 were done by my colleague, Huynh Thi Le Duyen. The 
serodiagnostics (in-house IgM/IgG capture ELISAs) for the patients involved in the 
various studies were done by a number of different colleagues at intervals over the 
two years that these studies were running. 3) For the work described in Chapter 5 ,1 
carried out all the laboratory work performed in Singapore, under the supervision of 
Professor Martin Hibberd, but my colleagues in the Dengue Group at OUCRU helped 
me with the serology assays, T cell phenotyping, and cytokine measurements.
For the statistical analysis and model development I worked under close supervision 
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Chapter 1
Chapter 1 
INTRODUCTION
1.1 Dengue
Dengue is the most important arboviral disease affecting humans, and represents a 
major burden for healthcare services in tropical regions of the world. It can be caused 
by any one of four serotypes of dengue virus (DENV) and is transmitted by mosquito 
vectors, primarily Aedes aegypti. Dengue is also known as breakbone fever and is 
usually characterized by symptoms such as fever, headache, muscle and joint pains 
and skin rash. However, the clinical manifestations vary from a mild self-limited 
febrile illness, through to severe and occasionally life threatening disease. 
Complications include an unusual plasma leakage syndrome that may result in 
hypovolaemic shock, coagulation disturbances sometimes accompanied by bleeding, 
and organ impairment.
The first record of dengue can be found in a Chinese encyclopedia of disease 
symptoms and remedies that was published during the Chin Dynasty (265 to 420 AD) 
(Gubler 1998). Several epidemics of possible dengue were reported in French West 
Indies (1635), Panama (1699), Indonesia (1779), Egypt (1780) and Philadelphia 
(1780). During 1779-1780, major epidemics of a disease consistent with dengue 
occurred across Asia, Africa and North America. Following this, large epidemics 
were occasionally recorded until World War 2. However, the ecological disruption 
that occurred during the Second World War allowed dengue to spread and become 
endemic in many regions. The world’s first recorded epidemic of severe dengue 
(dengue hemorrhagic fever -  DHF) occurred in the Philippines from 1953 to 1954. 
Since then, epidemics of DHF have been reported from many regions of Asia, 
America and Africa [2, 3].
Dengue has now become a major global public health concern. Figure 1-1 shows 
annual dengue incidence and the number of countries where dengue was recorded 
from 1955 to 2007 as reported by the World Health Organization (WHO) [1]. The
1
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spread of dengue is also been in Figure 1-2, which shows a map of dengue serotypes 
notified from 1943 -  2013 [4]. In 2008, more than 1.2 million cases were officially 
reported across the Americas, South East Asia and the Western Pacific. This increased 
to over 2.3 million in 2010. It has been estimated that there are about 50-100 million 
cases of dengue infection annually, with 2.5 billion people (over 40% of the world’s 
population) at risk [http://www.who.int/mediacentre/factsheets/fsll7/en/]. However, 
these figures might substantially underestimate the disease burden. Using modeling, 
Bhatt et al. estimate there to be 390 million dengue infections per year, of which 96 
million are symptomatic [5]. Very little data on case fatality rates (CFR) is available 
but, when available, CFR varies by geographical location, depending mainly on the 
level of monitoring available, as well as on the training and experience of the 
clinicians responsible for management. In Indonesia, India and Myanmar rates of 3.- 
5% are reported, while very low mortality (0.2%) has been reported from Thailand 
[1].
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Figure 1-1: Global burden of dengue. The bars show the annual numbers of dengue 
cases and the line shows the number of countries reporting dengue [1]
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1.2 Dengue epidemiology in Vietnam
Dengue was first notified in Vietnam in 1959. Because of the difference in climate 
patterns between the north and the south of Vietnam, dengue status is different in the 
two regions. With cooler weather, dengue ha s not been a major concern in the north 
until recently when dengue case numbers began to increase and large outbreaks were 
recorded, notably a very large outbreak in 2009 [6]. The status is more serious in the 
south. Between 2001 and 2010, 592,938 dengue cases were notified from 19 
provinces of the south of Vietnam [7], and on average more than 59,000 cases were 
reported annually. Between 1996 and 2009, 132,480 patients were hospitalized to one 
of three main hospitals (Hospital for Tropical Diseases, Children’s Hospital Nol and 
Children’s Hospital No2) in Ho Chi Minh City and diagnosed with dengue. Among 
them, there were a total of 14,079 dengue shock syndrome (DSS) cases, most of 
which were children (96.6%). The case fatality rate (CFR) was higher in DSS patients 
compared to non-DSS patients. Fortunately however, there has been a clearly 
decreasing trend in CFR in the last decade from 0.64% in 1996 to 0.10% in 2004 [8]. 
Though the number of deaths caused by dengue is relatively small, the high number 
of patients requiring assessment, and potentially hospitalization for supportive 
management, not only results in a major burden for health service systems in Vietnam 
and other countries endemic for dengue, but also represents a significant drain on the 
national economies of these countries.
Figure 1-3 shows the upward trend of notified dengue cases in the last few decades 
for both the north and the south of Vietnam. However it is also important to note that 
dengue has been recorded throughout the country, including from the central 
highlands and along the coastal provinces [9-11]. Although cases are recorded 
dispersed through the year, many cases occur during the rainy season when the 
transmission season varies somewhat among the different regions and provinces, in 
line with different weather patterns [7].
4
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Figure 1-3: Incidence of dengue in Vietnam [6, 8]. Graph A shows the incidence of 
notified dengue cases in Hanoi from 1998 to 2009. Graph B shows the annual 
incidence of hospitalized dengue in 20 provinces of southern Vietnam from 1996 to 
2008.
1.3 Dengue virus
Dengue virus is a positive sense, single stranded RNA virus, belonging to the genus 
Flavivirus of the Flaviviridae family. The dengue genome is approximately 1 lkb. It 
encodes three structural proteins: capside (C), membrane (M) and envelop (E); and 
seven non-structural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5. The 
structural proteins are necessary components of dengue virions and the non-structural 
proteins have functions related to virus replication.
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Although dengue antigens have been identified in a variety of human tissues such as 
liver, kidney, brain, skin, lung, spleen, heart and kidney, virus infection has only been 
confirmed in peripheral lymphocytes and macrophage and reactive splenic lymphoid 
cells [12-18].
Virus entry begins with the attachment of a virion to surface receptors of host cells, 
and then the virus penetrates the host cell mainly via clathrin mediated endocytosis 
[19-22]. Several molecules have been reported as receptors of DENV so far, for 
example C-type lectins such as dendritic cell-specific ICAM3-grabbing non-integrin 
(DC-SIGN) and C-type lectin domain family 5 member A (CLEC5A), mannose 
receptor, glucose-regulating protein 78 (GRP78/Bip), CD 14, heparan sulfate (HS), 
and glycosphingolipids -such as neolactotetraosylceramide (nLc4CER) [22-29]. 
Briefly, receptor-bound virus is taken up by clathrin coated vesicles, which then 
deliver to early endosomes which take the virus to late endosomes. Due to the low pH 
conditions of the endosomes, the viral E glycoprotein changes its conformation and 
the E-homodimer dissociates and generates a fusion loop which then inserts into the 
target cell membrane and forms a bridge between the virus and the host cell. E protein 
trimers then fold into a hairpin-like structure, thus bending the target membrane 
towards the viral membrane and leading to fusion. Following fusion, viral RNA is 
released into the host cell cytoplasm and begins the process of replication and 
translation [22]. In vitro, dengue was found to form plaques on mammalian cells. 
However, in vivo, the virus does not lyse target cells to release virions; instead, after 
assembly, dengue virions are secreted via a process of exocytosis [30].
1.4 Mosquito vectors and transmission
Aedes aegypti is the main vector for the dengue virus, although Aedes albopictus has 
been reported to transmit dengue in some regions. These mosquitoes have adapted to 
live in peri-urban and urban environments where humans are their main feeding 
target. They lay eggs in man-made containers which may fill with rainwater. These 
eggs then take about 7-14 days to progress through the larval and pupal stages to 
become adult mosquitoes. Aedes aegypti usually feed in the mid-morning and late
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afternoon. They become infectious when they bite infected patients with a significant 
viremia in their blood [31]. The virus replicates in the mosquito’s mid-gut before 
spreading throughout the mosquito’s body including to the saliva after 7-12 days [32]. 
After this time, it can be transmitted to healthy humans if an infectious mosquito bites 
them. Although vertical transmission has been demonstrated in a laboratory setting, 
this is rarely seen in the field. The potential for mosquitoes to transmit the virus can 
be influenced by changes in climate or environmental conditions, the interaction 
between populations of humans and mosquitoes, and the immunological status of the 
human population [11,33-35].
1.5 Dengue pathogenesis
Although a number of animal models for severe dengue exist, the relationships to 
human clinical disease are uncertain, and thus the findings from studies using these 
models must be interpreted with caution. As a result our understanding of dengue 
pathogenesis remains limited. However, similar to other infectious diseases, it is 
thought that the interaction of pathogen related factors and host factors, including the 
host immune response and genetic background, are all important. Since the severe 
manifestations of dengue occur relatively late in the disease course, often when the 
infecting virus is no longer detectable in plasma, immune mediated mechanisms are 
considered to play a significant role in pathogenesis. Factors that are thought to be 
relevant in dengue pathogenesis are summarized in this section and in Table 1.1.
1.5.1 Viral factors
1.5.1.1 Viremia
Currently, the viremia kinetics of dengue virus is still not clear, especially in the very 
early phase of illness around the time of fever onset. Plasma viremia is thought to 
peak early in the illness course, subsequently decreasing to undetectable levels by 
about day 5-6, sometimes up to day 8, of illness [36]. Conventionally, primary dengue 
infections (the first time that an individual is infected with one of the four serotypes)
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are said to be associated with lower plasma viremia than secondary infections (the 
second or subsequent time that an individual is infected, with a different serotype 
from the one that caused their primary infection). Higher plasma viremia, indicative 
of a higher overall viral burden, is also hypothesized to be associated with severe 
dengue. Evidence for this has come from a number of studies examining dengue 
viremia in regard to disease severity and immune status, with the results generally 
indicating higher viremia in severe dengue and in secondary dengue infections, as 
compared to uncomplicated dengue and primary infections [37-39]. There is some 
inconsistency however, with other studies showing no association between viremia 
level and disease severity or immune status [40-43].
However, to date most of the studies have involved relatively small numbers of 
patients, and the numbers infected with individual serotypes were even smaller. Only 
a few studies have investigated dengue viremia in serial samples from large numbers 
of patients and considered timing during the illness evolution [39, 44]. Among the 
studies in Vietnamese children, higher dengue viremia was shown in the early acute 
phase in primary DENV1 infections, compared to secondary infections assessed at the 
same time-point [44, 45]. These studies also showed higher viremia in DENV1 than 
in DENV2 infections.
1.5.1.2 Virulence
Another viral factor contributing to dengue pathogenesis is viral virulence. All four 
serotypes can cause severe dengue. Some studies have suggested that DENV2 is more 
likely to be associated with severe dengue [37, 46-49], while in some other studies 
DENV3 was associated with outbreaks of severe dengue [50, 51]. Dengue severity 
was not different among DENV serotypes in other studies [52].
Among the various DENV2 viruses a number of different genotypes have been 
identified -  in particular the American and the Asian genotypes - and there is 
evidence to support higher virulence associated with the Asian genotype [53]. With 
respect to DENV3 there are reports indicating that outbreaks of severe dengue were 
more likely to occur when there was emergence of a new clade of genotype [54, 55].
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1.5.1.3 Role of non-structural proteinl (NS1) in pathogenesis
NS1 is a glycoprotein with a molecular weight of 46-55 kDa that exists in many 
different forms at different cellular locations [56]. It exists as a stable homodimer on 
the surface membrane of infected cells, and as a soluble hexamer in plasma. Soluble 
NS1 has been found in plasma from the first day of fever onset and lasting up to 14 
days afterwards [57], and sNSl levels in the acute phase have been found to correlate 
with dengue severity [58, 59].
The evidence from in-vitro studies suggests that NS1 and anti-NSl antibodies may 
have important roles in dengue pathogenesis, especially in relation to plasma leakage, 
thrombocytopenia and coagulopathy. Thus sera from dengue patients, and purified 
antibodies against NS1, were found to act as anti-endothelial antibodies and induce 
apoptosis and cell lysis of endothelial cells via nitric oxide dependent pathways, thus 
leading to endothelial damage [60-62]. In addition, during the activation of 
endothelial cells, several inflammatory cytokines were also released, which, when 
combined with the endothelial apoptosis, may contribute to dengue vasculopathy [62]. 
Anti-NSl antibodies were also found to cross-react with platelets and inhibit platelet 
aggregation [63, 64], potentially contributing to the thrombocytopenia seen in severe 
dengue. Similarly anti-NSl antibodies and NS1 have been reported to cross react with 
several different molecules related to coagulation, such as human plasminogen and 
prothrombin/thrombin, thereby resulting in coagulation disorders [65-67].
Complement activation has also been suggested to contribute significantly to plasma 
leakage. Avirutnan et al (2006) found that both sNSl and cell-associated NS1 could 
activate complement with the enhancement or support of anti-NSl antibodies [68]. 
However, they also found that by binding to C4 or C4 binding proteins, NS1 
attenuates classical and lectin pathway activation of complement and protects DENV 
from complement-dependent lysis [69, 70]. In addition, sNSl/anti-NSl antibodies 
might facilitate dengue virus entry into a variety of cells [71, 72].
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1.5.2 Host factors
The most severe manifestations of dengue occur when viremia has already peaked and 
begun to decrease. This suggests that the pathogenesis of severe dengue is at least 
partly related to host immune activity.
1.5.2.1 ADE and the potential role of immune status
Though the immunopathogenetic mechanisms underlying severe disease remain 
poorly understood, it is known that, following an initial infection with one dengue 
serotype, a second or subsequent infection with a different serotype frequently results 
in more severe disease rather than resulting in immunological protection from the 
previous infection. It is hypothesized that the binding of residual heterotypic non­
neutralizing antibodies from the earlier infection with the new virus facilitates viral 
entry and replication, and in turn, the increased viral load causes an 
immunopathogenic cascade that alters microvascular function and results in a 
transient increase in vascular permeability that may be severe enough to cause dengue 
shock syndrome.
Halstead and O’Rourke suggested the role of non-neutralizing antibody in facilitating 
entry of dengue virus to host cells, and gave the first concept of antibody dependent 
enhancement (ADE) of viral infection [110]. In in-vitro experiments using peripheral 
blood mononuclear cells (PBMC) from people who were naive to DENV (i.e. who 
had never been infected with dengue before), they showed that a small innoculum of 
virus, that was not able to infect the PBMCs alone, could infect the same cells when 
non-neutralizing dengue antibody was added to the culture medium. Higher viremia 
output was also seen in cell culture following supplementation with non-neutralizing 
antibody.
A lot of evidence from epidemiological studies supports the association of severe 
dengue and secondary infections. A prospective cohort study on about 2000 primary 
school children in Thailand from 1998 to 2000 showed an association between the 
presence of anti-dengue neutralizing antibodies to a previously encountered serotype 
with increased dengue severity [77]. In addition, studies on infants indicate that in the
12
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initial months after birth maternal antibodies protect the infant from dengue, but that 
when the antibody levels decrease to low levels the risk for severe dengue increases 
[76]. Thus maternal antibodies transmitted to the baby prior to birth appear to function 
similarly to antibodies from a previous infection in older subjects, and a primary 
dengue infection occurring during the first year of life presents a clinical phenotype 
similar to a secondary infection in later life. A birth cohort study in Vietnam also 
confirmed the temporal association of infection enhancing activity of plasma from 
healthy children who had never had dengue before and age related case epidemiology 
during the first year of life [78]. The kinetics of the antibody response is also known 
to differ between primary and secondary dengue infections. In primary infections, 
IgM antibody develops rapidly, is detectable on day 3-5 of illness, reaches a peak two 
weeks later, and then declines to undetectable levels within 2-3 months. IgG appears 
later in the infection course, from the second week of illness onwards. By contrast in 
patients with secondary dengue, although the IgM time-course is similar the antibody 
levels achieved are thought to be significantly lower, while IgG appears in high titer 
either before or simultaneously with IgM [111]. In addition, IgG avidity is higher in 
secondary than primary infections [112].
It is important to note however, that although the ADE hypothesis helps to explain the 
association of secondary dengue infections and disease severity, it cannot explain the 
severe cases, including DSS, sometimes seen with primary infections [113].
1.5.2.2 Role of cellular immunology in dengue pathogenesis
Another hypothesis that has been proposed to explain the association of secondary 
heterotypic infection and severe dengue is the role of original antigenic sin. In fact 
this principle was first suggested by Halstead et al who showed that the highest 
neutralizing antibody titers in acute or late convalescent sera were to a prior viral 
serotype rather than to the current serotype [79]. However, Mongkolsapaya et al 
expanded on this idea, reporting that T cells likely play an important part in dengue 
pathogenesis based on this principle [80]. They found that in secondary infections, T 
cells have a relatively low affinity for the current serotype but have higher affinity for 
the serotypes from past infections. They hypothesized that T cells with low affinity to
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the current serotype would be less effective at clearing the virus, thus potentially 
promoting immunopathology. However, this hypothesis is currently being challenged 
by work from Weiskopf et al, who found that T cell responses shifted from serotype- 
specific responses in primary infection toward conserved responses in secondary 
infection. In addition, no significant difference in the magnitude or avidity of T cell 
responses between serotype-specific and conserved responses was found [114].
T cells have been shown to be activated in the acute phase of dengue, with higher 
levels in severe dengue compared to dengue patients, and with the activation of CD 8+ 
T cells being more profound than CD4+ T cell [81] [83]. As reviewed by Kurane et al, 
activated T cells are hypothesized to release cytokines, especially in more severe 
cases [83]. Increased levels of many different cytokines have been observed. Studies 
in Thai, Vietnamese and Indian children and infants all showed an increase in IFN-y, 
TNF-a in more severe dengue cases (DHF) compared to uncomplicated dengue (DF) 
or healthy patients [86, 88, 90]. Other studies reported increases in IL-10, IL-6 and 
IL-8 [85, 87, 89]. These inflammatory factors are hypothesized to mediate the 
increase of vascular permeability which leads to the severe complications of dengue, 
although the mechanism by which this occurs remains unclear.
In addition to T cells, other immune cells have been implicated in the host immune 
response against dengue, for example, dendritic cells (DC), antigen presenting cells 
and natural killer cells (NK. cells). Both DC and NK cells were found to be activated 
in acute dengue and to release cytokines, which in turn are thought to contribute to 
enhanced endothelial permeability and plasma leakage [78, 82, 84,115, 116].
1.5.2.3 Host genetics
A number of studies at both genome and transcription levels have been conducted to
identify genetic factors associated with severe dengue. At the level of genome, both
genotyping/polymorphism examination, and genome wide association studies have
been used to identify alleles or genotypes associated with dengue/severe dengue.
Human leukocyte antigens (HLA), which participate in host immune responses by
presenting peptides to lymphocytes, have been investigated the most extensively, and
associations both with severe dengue and with protection from severe disease have
14
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been identified [92-94, 98, 100, 103, 105]. Associations with many other genes that 
encode for proteins related to host immune responses have also been examined and 
both susceptibility and protective relationships identified. Examples include the 
following: cytokines such as tumor necrosis factor alpha (TNF-a), transforming 
growth factor-beta 1 (TGF-pl), lymphotoxin alpha (LTA-a) and interleukin 10 (IL- 
10); FcyRII, which mediates viral entry in secondary dengue via antibody dependent 
enhancement; vitamin D receptor, an immune mediator expressed on monocytes and 
activated B and T cells; transporter associated with antigen processing (TAP) and 
human platelet antigen (HPA); mannose binding lectin (MBL), one of the first 
molecules acting in defense against infectious agents; and the JAK-type 1 interferon 
pathway [91, 95, 99, 101, 102, 104, 117]. A recent genome-wide association study 
involving 2000 Vietnamese children with DSS and 2000 controls found susceptibility 
loci for shock at MICB and PLCE1 [96].
Currently, microarray technology is being used extensively to investigate the 
pathogenesis of many infectious diseases including dengue at the level of 
transcription, i.e. gene expression. Though the results have not always been 
reproducible in different research studies, up-regulation of some genes related to host 
immune responses have been found in association with severe dengue: genes related 
to neutrophils or innate immune responses; type I interferon pathways, apoptosis, IL- 
6, NF-kB and IL-10 signaling pathways; T and NK lymphocyte response and anti­
inflammatory reaction [59, 106-109]. Other studies have found associations with 
genes involved with metabolism, especially those related to mitochondrial ribosomal 
proteins and repair/remodeling associated with severe dengue [97,109].
1.6 Diagnosis and clinical management
1.6.1 Clinical manifestations and routine laboratory findings
Following the bite of an infected mosquito there is a 3-7 day incubation period. The 
illness starts abruptly and follows 3 phases -  the febrile phase, the critical phase and 
the recovery phase [118].
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1.6.1.1 Febrile phase
The febrile phase starts with the abrupt onset of a high fever. Early in the course of 
illness dengue patients often present with facial flushing, skin erythema, body aches, 
myalgia, arthralgia, headache, anorexia, nausea and vomiting. These signs and 
symptoms also appear in other febrile illnesses (OFI) that are common in dengue- 
endemic regions and can therefore be confused with dengue, for example measles, 
typhoid, leptospirosis, and influenza. Other signs that are also commonly observed in 
dengue patients in this initial phase are mild hemorrhagic manifestations such as 
petechiae, bruising, nose or gum bleeding and a palpable liver. Laboratory findings 
include a decrease in white blood cell count and platelet count. This phase lasts for 2- 
7 days.
1.6.1.2 Critical phase
The critical phase occurs around the time of defervescence, usually between days 3-7 
of illness, when the temperature drops to 37.5-38°C or less. While most patients start 
to improve at this time, a small proportion of people develop complications, in 
particular an unusual vasculopathy characterized by endothelial dysfunction and 
particularly affecting the microvasculature. The endothelial dysfunction results in 
increased vascular permeability and a plasma leakage syndrome that may be severe 
enough to cause hypovolaemic shock, and potentially death, if left untreated. There is 
some evidence to suggest that plasma leakage begins early in the dengue course, 
during the febrile phase. In a small proportion of cases, the plasma leakage is very 
profound with evidence of increased hemoconcentration, hypoproteinemia, pleural 
effusions and ascites. As leakage progresses compensatory mechanisms lead to a 
narrowing of the pulse pressure to maintain adequate circulation. When the pulse 
pressure narrows to less than 20 mm Hg, the degree of leakage becomes critical and 
the patient often develops tachycardia and cool, clammy skin; at this point DSS is 
diagnosed and the patient needs urgent fluid resuscitation. If shock is prolonged, poor 
organ perfusion may result in organ impairment, metabolic acidosis, and disseminated 
intravascular coagulation. Severe bleeding is sometimes associated with DSS, 
although usually bleeding is not severe even during the critical phase. During this
16
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phase, coagulation abnormalities and thrombocytopenia are also commonly observed. 
Typically the platelet count begins to decrease during the febrile phase and reaches 
the nadir around day 5-6 of illness, i.e. during the critical phase.
1.6.1.3 Recovery phase
In the majority of patients the critical phase last for 48-72 hours, following which they 
enter the recovery phase. Laboratory abnormalities gradually return to the normal 
range and the clinical features improve. The three phases of dengue are illustrated in 
( Figure 1-4A [1].
1.6.2 Clinical classification
As described above the clinical presentation of dengue varies widely. While the 
majority of patients infected with dengue recover after a short illness, a small 
proportion of patients progress to vasculopathy with increased vascular permeability, 
coagulation abnormalities, and bleeding manifestations. Previously, WHO classified 
symptomatic dengue into dengue fever (DF), and dengue haemorrhagic fever (DHF) 
grades I to IV, with grades III and IV alternatively called dengue shock syndrome 
(DSS). In 2009, because of some difficulties in application of this classification in 
practice, WHO issued a new guideline which classified symptomatic dengue into 
dengue with and without warning signs, and severe dengue (Figure 1-4B). Patients are 
classed as having severe dengue if they have any of the following criteria: severe 
plasma leakage leading to shock and/or fluid accumulation with respiratory distress; 
severe bleeding; and severe organ impairment. However, it has to be noted that even 
dengue patients without warning signs may develop severe dengue [1].
1.6.3 Laboratory diagnosis
A number of different laboratory techniques are currently used for dengue diagnosis. 
Each technique has advantages as well as disadvantages that together make it suitable 
for specific purposes.
18
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1.6.3.1 Virus isolation
Serum, plasma or any biological specimens for viral culture should be collected early 
in the infection, during the period of viremia (2 to 3 days prior to, and up to 5 days 
after, the fever onset) [37]. Several systems have been developed for virus isolation, 
including mosquito systems, mouse brain inoculation, and culture in cell lines. 
Among them, mosquito inoculation is the most sensitive method. However, both 
mosquito and mouse brain inoculation are difficult and expensive techniques 
requiring particular safety facilities.
Cell lines are more widely used for dengue virus isolation. DENV is isolated by 
incubating the biological specimen with a suitable cell line, usually C6/36 cells (a 
mosquito cell line) or vero or BHK cells (mammalian cell lines). Infected cells are 
subsequently detected using DENV serotype-specific monoclonal antibodies by 
immunofluorescence assay. Common to all virus isolation methods, the sensitivity or 
isolation rate depends on the mosquito species or cell line chosen, the day of illness at 
sampling and the immune status of the patient. Viral culture is still the gold standard 
for dengue confirmation; however it is time consuming and has limited sensitivity, 
which makes it unsuitable for routine diagnosis.
1.6.3.2 Serological diagnosis
Serological tests target anti-DENV antibodies. IgM and IgG capture enzyme-linked 
immunosorbent assays (ELISA) (MAC and GAC) are widely used for dengue 
diagnosis. This is based on the principle that anti-dengue IgM and IgG antibodies 
increase in response to dengue infection. Although IgM can be detected as early as 3- 
5 days after illness onset, paired samples demonstrating seroconversion are required 
to make a definitive diagnosis. In addition, cross-reactions with other flaviviruses 
have been noted [119-121]. Epidemiological information about the prevalence of 
other flaviviruses should therefore also be included in the interpretation of serology 
results. Besides MAC and GAC, other serological methods such as anti-dengue IgG 
indirect ELISA, plaque reduction neutralization tests (PRNT), and haemaglutination 
inhibition (HI) are also used for dengue diagnosis. These tests are especially useful for
19
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dengue sero-surveillance, and have been employed for differentiating between 
primary and secondary infections.
HI is based on the phenomenon that red blood cells will agglutinate in the presence of 
dengue antigen [1]. Antibodies in dengue patients’ blood are able to neutralize the 
dengue antigens thus inhibiting this haemagglutination reaction. World Health 
Organization recommendations for using the HI test to differentiate between primary 
and secondary dengue requires paired samples with at least 7 days interval. In a 
primary infection, low levels of HI antibodies are seen in the first sample (SI). The 
titer then rises in the second sample but only to relatively low levels, usually lower 
than 1:1280. In contrast, the HI antibody titer rises rapidly in a secondary infection, 
usually exceeding the cut-off of 1:2560. However the HI technique is limited by 
several problems, in particular the test is time consuming to perform and different 
laboratories now use different cut-offs. Another disadvantage of HI is the fact that it 
requires paired samples, and in clinical settings the second sample is frequently not 
obtained as the patient has already recovered.
Recently, studies on dengue vaccines as well as evidence from sero-surveillance have 
indicated that levels of neutralizing antibodies as measured by PRNT correspond 
poorly to the level of protection against infection [122, 123]. However, PRNT are still 
considered to be a reliable method to detect previous exposure to different dengue 
serotypes, especially when performed in late convalescence, when the acute 
inflammatory response has subsided and cross-reactivity between serotype responses 
has decreased. Previous studies have demonstrated that in primary infections only 
antibodies against the DENV serotype that caused the recent infection are detected 
and measured in late convalescence, while in secondary dengue antibodies against 
several serotypes are present [124]. However, the test is cumbersome and time- 
consuming to perform and the sampling time-frame -  several months after recovery -  
is not practical for clinical management. Even for research obtaining samples such a 
long time after recovery is challenging.
Because of the importance of knowing an individual’s immune status in pathogenesis 
studies of natural human infections, and the complexity of HI or PRNT assays,
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several groups have assessed alternative, more practical, methods to differentiate 
primary from secondary dengue infections. Most of these systems are based on 
knowledge of the expected antibody kinetics during dengue infections. Innis et al 
suggested using the IgM/IgG ratio with a cut-off of 1.78 [125]. Other authors also 
used IgM/IgG ratio but with different cut-offs, of 1.2 or 1.4 [126, 127]. In addition 
differences in absolute IgG levels and in avidity have been used by others to 
differentiate between primary and secondary infections [37, 127-129]. Widespread 
application of these methods is limited by the fact that most of the assays used were 
in-house assays, and in some studies the number of samples used for algorithm 
development was small. In addition, although levels of anti-dengue IgM and IgG 
clearly change during the acute illness, aside from the method presented by Cordeiro, 
none of the other methods take into account the evolving nature of the immune 
response over time.
1.6.3.3 DENV nucleic acid detection
Reverse transcriptase polymerase chain reaction (RT-PCR) can be used to detect the 
nucleic acid of DENV in a patient’s blood during the viremic phase of dengue, up to 8 
days after illness onset [130]. Various primer and probe sequences specific for 
DENV, or for a particular DENV serotype, have been developed for conventional RT- 
PCR and for real-time RT-PCR. These techniques now permit identification of the 
serotype, and quantification of the level of plasma viremia, with good sensitivity, 
specificity and limit of detection, especially for real-time RT-PCR. Multiplex real­
time RT-PCR that allows detection of DENV serotypes in a single reaction has also 
been developed [131]. However, despite the overall advantages, the application of 
real-time PCR is limited by the requirement for expensive laboratory equipment and 
highly trained technicians.
1.6.3.4 Antigen detection
Currently a number of commercial tests have been developed for detection of the NS1 
antigen; these have high specificity for DENV infection, and have been used
21
Chapter 1
successfully for early diagnosis. However, the sensitivity varies depending on the 
DENV serotype, the immune status of the patient (primary or secondary infection), 
and the day of illness when the patient is assessed [132,133].
1.6.4 Case management and disease prevention
Despite the increasing importance of dengue globally, current management guidelines 
continue to rely on supportive care and there are no specific therapies available for 
management of severe cases. The mainstay of treatment remains early recognition, 
regular monitoring and careful fluid management.
Several strategies are actively being investigated at the present time. Firstly there is 
considerable interest in the utility of antiviral reagents against dengue. An effective 
antiviral therapy could help a) to decrease the burden on healthcare services caused by 
high requirements for hospital admission in endemic areas (and by extension the 
economic burden on governments), and b) could help to reduce transmission of the 
virus to mosquitoes, thereby reduce ongoing transmission to new human hosts. There 
is increasing interest from industry in developing antiviral agents for dengue. These 
compounds target a number of possible virus and host proteins aiming to disrupt the 
virus life cycle by altering adhesion, RNA replication, viral assembly or other crucial 
events. Although many agents have been tested in-vitro (see review by Lim et al 
[134]), only a few have been assessed for efficacy and safety in formal clinical trials 
in humans. These include chloroquine, balapiravir (a polymerase inhibitor developed 
for treatment of the related virus, hepatitis C) and celgosivir (an iminosugar which 
participates in glycoprotein synthesis) [130, 135, 136]. Unfortunately, although the 
safety assessments were satisfactory, there was no evidence in these trials of a benefit 
in reducing plasma viremia or preventing the development of complications. 
Lovastatin, a drug primarily used to reduce cholesterol levels but which also has been 
reported to inhibit dengue virus replication in-vitro and to have endothelial stabilizing 
properties, is currently undergoing clinical testing for its efficacy and safety on 
dengue patients [137-139].
Another strategy that is being investigated involves suppression of the host immune
response, which is hypothesized to contribute to the development of severe dengue, in
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particular the endothelial dysfunction/vasculopathy. Prednisolone is a potent 
corticosteroid anti-inflammatory agent which is commonly used to treat diseases 
where the host immune response is thought to make a significant contribution to the 
severity of the disease, such as asthma [140, 141]. A number of clinical trials have 
examined the efficacy of corticosteroids in children with DSS, but with inconsistent 
results. However most of the work was carried out over 25 years ago, and the studies 
were small, underpowered, and lacked stringent randomization and clear allocation 
concealment [142-144]. Notably in these studies, the steroids were used after the 
onset of shock, which is now considered to be too late to be helpful. An alternative 
strategy that is currently being assessed is early use of corticosteroid therapy during 
the febrile phase in an attempt to prevent progression to severe disease. One 
randomized, blinded, placebo-controlled clinical trial of early prednisolone use was 
recently conducted in Vietnam, with the primary goal of assessing safety during the 
phase of active viral replication. The trial did not show evidence of harm with early 
prednisolone use compared to placebo, but also no evidence of prednisolone efficacy 
in preventing DSS. However it should be noted that the trial was not powered to an 
efficacy endpoint [36].
A number of vaccines for dengue are in development and several are undergoing 
clinical assessment [145, 146]. The most advanced is a recombinant tetravalent live- 
attenuated vaccine (CYD-TDV) developed by Sanofi-Pasteur. The vaccine comprises 
4 recombinant live attenuated dengue viruses, expressed on a yellow fever virus 17D 
backbone. CYD-TDV has now been tested in phase 1, 2 and 3 clinical trials in 
thousands of healthy children from many countries, and has shown a good safety and 
immunogenicity profile (based on PRNT assays) [122, 147-153]. In the most recent 
report of the phase 3 trial involving 10,275 healthy children in Southeast Asia, the 
vaccine efficacy varied according to the serotype, being highest for DENV3 (78.4%) 
and lowest for DENV2 (35%), for an overall efficacy of 56.5% (95%CI 43.8 -  
66.4%). The vaccine efficacy against severe dengue (DHF) and hospitalization were 
better, at 80% (95%CI 52.7 -  92.4) and 67.2% (95%CI 50.3 -  78.6) respectively 
[153].
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1.7 Knowledge gaps and thesis objectives
Despite the efforts invested in studying dengue pathogenesis, the mechanisms 
underlying the severe disease manifestations remain poorly understood. Although it is 
not exclusive, a strong association between severe dengue and secondary infection is 
apparent, and in many research studies differentiation between primary and secondary 
infections is an important initial step to allow detailed exploration of mechanistic 
hypotheses. However, the methods currently in use are quite variable, often not 
practical, and usually do not take into account the evolving nature of the immune 
response over time. Therefore in the first part of my thesis (see Chapter 3) I set out to 
establish novel algorithms that permit differentiation of primary from secondary 
dengue infections at any day of illness with high accuracy, with the aim of applying 
the algorithm with the best performance to research investigating dengue viremia 
kinetics.
Viral burden is considered by many to be a major factor influencing disease severity 
and outcome in dengue, but existing knowledge of the magnitude and kinetics of 
plasma viremia (used as a surrogate measure of total viral burden) in association with 
different dengue serotypes, primary versus secondary immune status, and in relation 
to clinical disease severity, is limited and inconsistent. This is at least partly due to the 
small number of cases that have had detailed assessments in previous studies. In 
chapter 4, I report viremia kinetics in a variety of circumstances with serial samples 
from a large number of well characterized patients covering the full clinical disease 
spectrum.
As well as improving our understanding of the pathogenetic mechanisms underlying 
dengue. Knowledge of the expected magnitude and kinetics of viremia in different 
circumstances should prove invaluable for the design and conduct of therapeutic trials 
aimed at preventing and/or treating severe dengue. A randomized, placebo-controlled 
double-blind trial assessing the safety of early oral corticosteroid therapy in dengue 
patients was conducted at the Hospital for Tropical Diseases, Ho Chi Minh City, 
Vietnam between August 2009 and January 2011. In chapter 5, I focus on
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investigating the effect of early prednisolone therapy on dengue viremia and on the 
whole blood transcriptional profile of patients enrolled in the study.
In summary, my work is aimed at investigating the following questions:
>  Is it possible to develop algorithms to differentiate primary and secondary 
dengue infections based on serological responses using single specimens 
obtained on any day of illness during the acute phase with high accuracy?
> Are there measurable differences in DENV kinetics according to the 
infecting serotype and the host immune status? Specifically, does viremia 
kinetics differ between serotypes in patients with the same immune status? 
And is the viremia kinetics of the same DENV serotype actually different 
between primary and secondary infections? Finally is plasma viremia in 
the early days of illness independently associated with clinical outcomes 
from dengue?
> Although early therapy with prednisolone did not have a demonstrable 
clinical effect on patient outcomes in our recent study, did prednisolone 
influence viremia, antigenemia kinetics, immune responses or the whole 
blood transcriptional profile in the dengue patients? If so can this 
knowledge help us to understand more about dengue
immunopathogenesis?
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Chapter 2 
MATERIALS AND METHODS
In this chapter, I will describe the laboratory techniques I used in my studies. 
Information on the clinical studies, patient enrolment, and clinical definitions, as well 
as the methodology for the statistical analyses, will be presented in detail later, in the 
relevant chapters.
2.1 RNA extraction
Supernatant from DENV 1-4 viral culture in C6/36 cells and molecular water (Sigma) 
were used as external controls (positive and negative controls respectively) which 
were included whenever experiments were conducted. Equine arteritis virus (EAV) 
was added to all samples before extraction as an internal control to control the 
uniformity in all reactions.
QIAamp viral RNA mini kit (Qiagen) was used for the ENA extraction following the 
manufacturer’s instructions. Firstly, 160pi of patient plasma, positive and negative 
controls, already mixed with 20pl EAV, was added into RNA free 1.5ml micro 
centrifuge tubes containing 560pl of prepared buffer AVL containing carrier RNA. 
The mixture was vortexed and incubated for 10 minutes at room temperature. In the 
next step, 560pl of ethanol was added to the tube, and then mixed by pulse vortex for 
15 seconds. This was followed by a short spin to remove the drops from the lid. 600pl 
of the lysate was carefully transferred to QIAamp spin columns and then centrifuged 
at 8000 rounds per minute (rpm) for 1 minute. The spin column was transferred to 
another clean 2 ml collection tube. The same steps were repeated until all the lysate 
had been loaded to the column. Two washes were then performed, the first using 
500pi of washing buffer of AW1 and the second using washing buffer of AW2. The 
RNA was eluted from the column with 60pl of elute buffer AVE for 10 minutes at 
room temperature and collected by centrifuging for 2 minutes at 14000 rpm. The 
RNA elute was kept at minus 80°C until used.
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2.2 Two-step real-time multiplex reverse transcription (RT-) PCR 
2.2.1 Procedure
Two-step real-time RT-PCR was performed as described elsewhere [154]. As the 
name indicates, the procedure includes two steps - firstly, reverse transcription for 
cDNA synthesis and then real-time PCR for quantification of the cDNA number in 
the samples.
2.2.1.1 cDNA synthesis
8  pi RNA as extracted above was mixed with 5pi of Mix 1 (lp l of lOOpg/ml random 
hexamers, lp l of lOmM dNTP and 3pi molecular water) and incubated at 65°C for 5 
minutes. After the incubation,, the reaction was transferred immediately on ice, where 
7pl of Mix 2 (4pl of 5X buffer, lp l DTT, 0.4pl of 40U/pl RNase inhibitor, 0.2pl of 
200U/pl Superscript III Reverse Transcriptase and 1.4pi molecular water) was added. 
The reaction was incubated at 50°C for 60 minutes then 72°C for 5 minutes. cDNA 
product was kept at -20°C until used.
2.2.1.2 Real-time PCR
Each PCR reaction only detects and quantifies one DENV serotype. The sequences of 
specific primers and probes for DENV serotypes and EAV were listed in Table 2-1. A 
linearized plasmid containing the cloned target amplicon, which was diluted in 1 0  
fold series, was used as standard for the real-time RT-PCR reaction. Firstly, the PCR 
master mix was prepared as described in Table 2-2, then 4 pi of cDNA of the patients’ 
samples, positive, negative controls or standard DNA was added to the reaction. PCR 
reactions were run on thermo cycler (Biorad) as follows: 95°C for 15 minutes; and 45 
cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds and 
fluorescent measurement.
2.2.2 Controls and standards
Results of an experiment were accepted if positive and negative controls gave correct 
results. In addition, the Ct values of the internal controls of all samples had to be in 
the allowable range. In cases where some values were out of the allowable range, the 
results would be accepted if the criteria in Table 2-3 were met.
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Table 2-1: Dengue and EAV specific primers and probes for two-step real-time 
RT-PCR
Primer/Probe Primer/Probe Sequences Position
Product 
size 
in base
DENV1 - 
Forward ATCCATGCCCACCAYCAATG 9960 - 9980 162DENV1 - 
Reverse CAGGGATCCACACCAYTGATC
1 0 1 0 0  - 
1 0 1 2 1
DENV2 - 
Forward
ACAAGTCGAACAACCTGGTCC
AT 9938 - 9941 178DENV2 - 
Reverse GCCGCACCATTGGTCTTCTC
10095 - 
10115
DENV3 - 
Forward TTTCTGCTCCCACCACTTTCAT 9719-9741 216DENV3-
Reverse TGGCGTTGGATGCYAGTCT 9915-9934
DENV4-
Forward GY GT GGT G AAGCC Y CTRGAT 9587 - 9607 178DENV4-
Reverse AGTGARCGGCCATCCTTCAT 9744 - 9764
EAV- Forward CATCTCTTGCTTTGCTCCTTAG 1847- 1868
133
EAV- Reverse AGCCGCACCTTCACATTG 1963 - 1980
DENV 1-Probe 5'(FAM)TCAGTGTGGAATAGGG1AMRA)
fTT GGATAGAGGAA3 '(T
DENV2-Probe 5' FAM GTT+T+Tg+T+CT+TC+C A+TCC A3 'BHQ-1 (+ indicates LNAbase)
DENV3-Probe
5*
(FAM)AAGAAAGTTGGTAGTTCCCTGCAGACCCCA3’(TAM
RA)
DENV4-Probe
5'
(FAM)ACTTGCCTCCTCTTYTTGAACGACATGGGA3’(TAMR
A)
EAV - Probe Cy5CGCGCTCGCTGTCAGAACAACATTATTGCCCACAGCGCG3’(BHQ3)
Y stands for C or T nucleotide, R for A or G.
The standard curves which were generated automatically by the Opticon software 
were accepted if R coefficient > 0.9.
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Table 2-2: Two-step real-time RT-PCR master mix components
Reagents
Working
concentration
pl/reaction
DENV1 (or DENV2, 3, 4) Forward primer lOpM 1.5
DENV1 (or DENV2, 3, 4) Reverse primer lOpM 1.5
EAV Forward primer lOpM 1.5
EAV Reverse primer lOpM 1.5
DENV1 (or 2, 3, 4) probe lpM 5
EAV probe 5pM 1.5
MgCl2 25mM 2.5
10X HotstarTaq buffer 10X 2.5
dNTPs lOmM 1
HotstarTaq 5U/pl 0.2
Molecular water 2.3
Total 2 1
Table 2-3: Interpretation of two-step real-time RT-PCR results
EAV/DENV
Result
(+/+) (+/-) (-/+> (-/-)
Pass Pass Pass Fail
2.2.3 Interpretation
The two-step real-time RT-PCR results were collected and analyzed using Opticon 
software (Biorad). The units of the RT-PCR are presented as copies/ml. Patient 
samples were defined as negative if the Ct value was higher than 40. The limit of 
detection (LOD) for each serotype was about 5,000copies/ml of plasma.
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2.3 One-step real-time multiplex reverse transcription (RT-) PCR
2.3.1 Procedure
The procedure for one-step real-time multiplex RT-PCR has been described elsewhere 
[131]. There are two sets of multiplex assays to detect i) DENV1, DENV3 and EAV 
or ii) DENV2, DENV4 and EAV simultaneously. Sequences of specific probes and 
primers for each DENV serotype and EAV are described in Table 2-4. A linearized 
plasmid containing the cloned target amplicon, which was diluted in 1 0  fold series, 
was used as standard for the real-time RT-PCR reaction.
Firstly, the PCR master mix was prepared as described in Table 2-5, then 6 pi of RNA 
(which had been previously extracted from the patient’s plasma), positive or negative 
controls, or standard DNA was added to the reaction. PCR reactions were run on a 
LightCycler II PCR machine (Roche) as follows: 61°C for 10 minutes; 95°C for 2 
minutes; and 45 cycles of 95°C for 15 seconds, 60°C for 30 seconds and fluorescent 
measurement. Signals were read at wavelength 498-580, 440-488 and 618-660 for 
DENV1/DENV2, DENV3/DENV4 and EAV respectively.
2.3.2 Controls and standards
Controls and standards for the one-step real-time multiplex RT-PCR were similar to 
the two-step real-time RT-PCR described above. In addition, the standard curves 
which were generated automatically by the LightCycler software were accepted if 
efficiency >1.7 and error <0.2.
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Table 2-4: Dengue and EAV specific primers and probes for one-step real-time 
multiplex RT-PCR
Primer/Probe Primer/Probe sequences (5’-3’)
Position Product size 
in base
DENV1- Forward ATCC AT GCCC A Y C ACC AAT 9865-9883
1 0 0
DENV1- Reverse TGTGGGTTTTGTCCTCC ATC 9945 - 9964
DENV2- Forward TCCATACACGCCAAACATGAA 9859 - 9879
125
DENV2- Reverse GGGATTTCCTCCCATGATTCC 9963 - 9983
DENV3- Forward TTTCT GCTCCC ACC ACTTT C 9591 -9610
118
DENV3- Reverse CCATCCYGCTCCTTGAGA 9691 - 9708
DENV4- Forward GY GT GGT GAAGCC Y CTRGAT 9587 - 9607
178
DENV4- Reverse AGTGARCGGCCATCCTTCAT 9 7 4 4 . 9 7 6 4
EAV- Forward CATCTCTTGCTTTGCTCCTTAG 1847- 1868
133
EAV- Reverse AGCCGCACCTTCACATTG 1963 - 1980
DENV 1-Probe
5' (FAM) TCAGTGTGGAATAGGGTTTGGATAGAGGAA
3'(BHQ1)
DENV2-Probe 5’(FAM) AGGGTGTGGATTCGAGAAAACCCATGG 3’(BHQ1)
DENV3-Probe
5'(Cyan500) AAGAAAGTTGGTAGTTCCCTGCAGACCCCA
3'(BHQ1)
DENV4-Probe
5'(Cyan500)TTCCCTCCTCTTYTTGAACGACATGGGAAAGGT
G 3'(BHQ1)
EAV - Probe
5’(Cy5)CGCGCTCGCTGTCAGAACAACATTATTGCCCACAG
CGCG 3'(BHQ3)
Y stands for C or T nucleotide, R for A or G.
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Table 2-5: One-step real-time multiplex RT-PCR master mix components
Reagents Workingconcentration pl/reaction
Mix of DENV 1 (or DENV2) Fw -  Rev primers 20pM 1
DENV1 (or DENV2) probe lOpM 0.28
Mix of DENV3 (or DENV4) Fw -  Rev primers 20pM 1
DENV3 (or DENV4) probe lOpM 0.28
Mix of EAV Fw - Rev primers 20pM 0.2
EAV probe IOjiM 0.08
Activator 1.4
Enhancer 20X 1
RNA master mix 2.7 7.4
H20 1.36
Total 14
2.3.3 Interpretation
The one-step real-time multiplex RT-PCR results were collected and analyzed using 
the LightCycler® 480 SW 1.5, the software provided with Lightcycler II PCR 
machine (Roche). The units of the RT-PCR are presented as copies/ml. The limit of 
detection (LOD) for each serotype was identified via a rigorous validation procedure, 
and is presented in the Table 2-6 [131]. Viremia levels that were lower than the LOD 
were considered to be negative.
Table 2-6: Limit of detection of one-step real-time multiplex RT-PCR assay
DENV1 DENV2 DENV3 DENV4
LOD
(copies/reaction) 5 1 5 10
LOD
(copies/ml
plasma)
300 60 300 600
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2.4 Capture IgM/IgG enzyme-linked immunosorbent assay (ELISA)
2.4.1 Controls
Acute plasma from Vietnamese confirmed dengue patients which gave strong positive 
results with the capture IgM/IgG ELISA were pooled to create the positive control. 
The negative control sample was a mixture of plasma from dengue-naive healthy 
adult volunteers who had just arrived from regions without known dengue 
transmission and who had negative results on the Panbio IgG indirect ELISA.
2.4.2 Procedure
The procedure for IgM/IgG has been described elsewhere [132, 155]. Briefly, 96 well 
plates (Maxisorp, Nunc) were coated with lOOpl/well of anti-human IgM (A0425, 
Dako) or anti-human IgG (12136, Sigma) at a dilution of 1:2000 in 0.05 M carbonate- 
bicarbonate buffer, pH9.6 (C3041, Sigma) overnight at 4°C. After 3 washings with 
phosphate buffer saline-TWEEN (PBST), each well was blocked with 200pl of 3% 
bovine serum albumin (BSA, A7906, Sigma) in phosphate buffer saline (PBS) for 2 
hours at room temperature. Next, the plate was washed again and then incubated for 2 
hours at room temperature with lOOpl/well positive, negative controls or samples 
which were diluted 1:100 in 0.1% BSA-PBS. After washing, the assay was continued 
by adding 100 pi of pooled DENV 1-4 antigen (pooled C6/36 cultures of DENV 1-4) to 
each well and incubating at 4°C overnight. Afterwards, the plate was washed and 
incubated with a cocktail of mouse monoclonal anti-DENVl-4 E protein antibodies 
(lOOpl/well) for 1 hour at room temperature. The antigen-antibody complex was 
detected with 100pi of 1:2000 diluted anti-mouse Ig Horseradish Peroxidase (HRP) 
(P260, Dako) for 1 hour in the dark at room temperature. The color reaction was 
developed with substrate o-phenylenediamine dihydrochloride (OPD, Sigma) in the 
dark for 30 minutes and then stopped by adding 50pl of 10% H2 SO4 . The optical 
density (OD) was read at 490nm with Microplate Reader and analyzed with 
Microplate Manager software (Biorad).
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2.4.3 Calculation and interpretation
All of the OD values of negative and positive controls and samples were normalized 
by subtracting to the mean background absorbance value (ODB) which was the mean 
OD of the blank wells where the sample and the DENV antigen was PBS. Negative 
and positive control means (NCM and PCM) were the mean of corresponding 
controls. The assay cut-off (CO) was defined as 5 times the NCM. Sample ratio (RS) 
was calculated by taking the normalized sample OD (ODS) minus the mean of 
background (ODB) and dividing by the assay cut-off: RS=(ODS-ODB)/CO. The 
result was interpreted as follows:
• If RS <0.8, result was interpreted as negative
• If RS >1.2, result was interpreted as positive
• If 0 . 8  < RS < 1.2, result was interpreted as equivocal
2.5 Anti-E protein IgG indirect ELISA
2.5.1 Controls
Acute plasma from Vietnamese confirmed dengue patients which gave strong positive 
results with the Panbio IgG indirect ELISA were pooled to create the positive control. 
The negative control sample was a mixture of plasma from dengue-naive healthy 
adult volunteers who had just come from regions without known dengue transmission 
and had negative results with Panbio IgG indirect ELISA.
2.5.2 Procedure
Firstly, 48 wells of 96 well plates (Maxisorp, Nunc) were coated with 50pl/well of a 
cocktail of four recombinant DENV 1-4 E proteins (Hawaii Biotech) at a 
concentration of 0.5pg/each serotype/ml in carbonate and bicarbonate buffer (C3041, 
Sigma) at 4°C, overnight. The remaining wells were uncoated. After washing 3 times 
the plates were blocked with 200pl/well of 3% bovine serum albumin (BSA, A 7906, 
Sigma) in PBS for 1 hour at room temperature. After washing again, lOOpl of 1:100 
diluted plasma, positive control or negative control was added to the coated and
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uncoated wells and incubated for 1 hour at room temperature. The assay was 
continued with washing and then adding lOOpl/well of goat anti-human IgG 
peroxidase conjugate. lOOpl of TMB was used as the substrate for color reaction for 
10 minutes in the dark at room temperature. The optical densities of the wells were 
measured at 45 Onm.
2.5.3 Calculation and interpretation
All of the OD values of negative, positive controls and samples were normalized by 
dividing by their own background absorbance value which was OD of uncoated wells. 
Negative and positive control means (NCM and PCM) were the mean of 
corresponding controls. The assay cut-off (CO) was defined as 5 times of NCM. 
Sample ratio (RS) was calculated by taking the normalized sample OD dividing by 
the assay cut-off. The result was interpreted as follows:
• IfRS <0.8, result was interpreted as negative
• If RS >1.2, result was interpreted as positive
• I f0 .8 < R S <  1.2, result was interpreted as equivocal
2.6 Panbio anti-dengue IgG indirect ELISA
2.6.1 Procedure
The Panbio anti-dengue IgG indirect ELISA was performed following the instructions 
of the manufacturer. Briefly, samples, negative controls, positive controls and 
calibrators were firstly diluted 1:100 with serum diluents and then added to the 96 
well-plate (lOOpl/well), which had been coated with dengue antigens by the 
manufacturer. The plate was incubated at 37°C for 30minutes. After washing 6  times 
with diluted washing buffer, to each well was added lOOpl of horse radish peroxidase 
(HRP) conjugated anti-human IgG. The plate was incubated for another 30 minutes at 
37°C. After another wash, lOOpl of TMB was added to each well and incubated for 10 
minutes in the dark at room temperature. The reactions were stopped with lOOpl of 
stop solution. The optical densities were measured at 45 Onm with reference filter of 
600-650nm.
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2.6.2 Calculation and interpretation
The cut-off value was a multiplication of the calibrator factor and the average value of 
absorbance of the 3 calibrators. The index value was calculated by dividing the
absorbance of the samples by the cut-off value, with the Panbio unit taken as 10 times
the index value. The interpretation of results was as follows:
• If index value < 0.9, result was interpreted as negative
• If index value >1.1, result was interpreted as positive
• If 0.9 < index value <1.1, result was interpreted as equivocal
2.7 Qualitative NS1 ELISA
2.7.1 Procedure
The Platelia™ Dengue NS1 Ag Kit (BIO-RAD) was used for qualitative sNSl assays 
and the procedure was as per the manufacturer’s instructions. Briefly, 50pl of diluent 
and 50pl of plasma or control solution (negative or positive) or calibrator (cut-off) and 
lOOpl of diluted conjugate were contributed to the plate. The reaction was incubated 
at 37°C for 90 minutes. After washing, 160pl of chromogen solution was added into 
each well and incubated for 30 minutes in a dark environment at room temperature. 
The color reaction was stopped using lOOpl/well of IN sulfuric acid solution. The 
optical density was read at 450/620 nm.
2.7.2 Calculation and interpretation
The sample ratio (RS) was calculated by dividing the optical density (OD) of the 
sample by the OD of the cut-off. The results of the assay were acceptable if the cut­
off OD > 0.2, and the RS of negative and positive controls was <0.4 and >1.5 
respectively. The result interpretation was as follows:
• If RS <0.5 - result was interpreted as negative
• If RS >1.0 - result was interpreted as positive
• If 0.5 < RS <1 .0 -  result was interpreted as equivocal
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2.8 Algorithm for laboratory confirmation of dengue [132]
A case was considered to have confirmed dengue based on the serology, PCR and 
NS1 results, using an algorithm previously established in our laboratory [132]. For 
serological diagnosis, two samples were required. The first samples (SI) were 
collected when patients first presented at the health facility, usually within 72 hours of 
fever onset. The second samples (S2) were collected on day 6 or more of illness, with 
a gap of at least 3 days between the two samples. Patients were confirmed as having 
acute dengue if  any of the following conditions were satisfied: i) positive with one of 
4 serotypes of DENV in PCR test or positive with NS1 test, or ii) IgM seroconversion 
in MAC ELISA from SI to S2, or iii) IgM positive in both SI and S2 with IgG 
conversion from SI to S2 or iv) IgM positive in both SI and S2 with a 20% rise in 
IgM in S2 (S2 IgM > 1.2 X SI IgM units). Patients were confirmed negative for 
dengue infection if they had negative PCR for all 4 serotypes, were negative for NS1 
and had negative IgM and IgG serology results in both SI and S2. Other conditions 
were defined as recent DENV infection (IgM positive in a single specimen, or in 
paired samples but with no significant (< 20% rise in units), or acute flavivirus 
infection (IgG seroconversion from SI to S2), or recent flavivirus infection (IgG 
positive in Si and S2), or indeterminate if none of the above conditions were met.
2.9 Plaque reduction neutralization test (PRNT)
The PRNT assay was conducted at Laboratory of Infectious Diseases (NIAID, NIH, 
USA) of Professor Steve Whitehead as described elsewhere [156, 157]. Strains of 
DENV 1 Puerto Rico/94, DENV2 NGC prototype, DENV3 Sleman/78, DENV4 
814669 were used for the PRNT assay. Briefly, plasma was heat inactivated at 56°C 
for 30 minutes. Next, a serial of 2-fold dilutions beginning at 1:10 were prepared in 
serum-free medium containing 0.25% human serum albumin. The virus which was 
previously diluted to 500 plaque-forming units/ml in medium containing guinea pig 
complement (Cambrex) at a complement fixation titer of 1:10 was added to equal 
volumes of diluted plasma and incubated at 37°C for 30 min. 0.1 ml of virus-serum 
mixture was incubated with monolayer cultures of Vero cells on 24-well plates for 60
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min at 37° C. After the incubation, the wells were overlaid with medium containing 
1% methylcellulose and 2%  fetal bovine serum and were incubated at 37°C for 4-5 
days. The plaques were visualized by immunoperoxidase staining, and a 60% PRNT 
(PRNT60) titer was calculated. The limit of detection was a titer of 10.
2.10 Cytokine quantification
IL-lp, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IFNy, TNFa and IP10 were 
quantified using Bio-Plex Precision Pro Assays, Human cytokine 10-Plex and Human 
IP10 (Biorad).
2.10.1 Procedure
The procedures were carried out according to the manufacturer’s instructions. Briefly, 
after pre-wetting the 96-well filter plate with 200jil of assay buffer, 50pl of the beads 
was added to each well and vacuum filtered. After washing, 50pl of standard control 
or sample was added to each well and incubated for 1 hour in the dark at room 
temperature. The assay was continued with vacuum filtering, washing, and incubating 
with 25pl IX detection antibody at room temperature in the dark for 30 minutes. After 
filtering and washing, the bead-cytokine-antibody complex was detected by 
incubating with 50pl of IX streptavidin-PE for 10 minutes in the dark at room 
temperature. After filtering and washing, 125pl of assay buffer was added to each 
well and the assay plate was shaken for 30 seconds at 1,100 rpm before acquiring data 
using a multiplex array reader from Luminex Systems (Bio-Plex 200 system from 
Bio-Rad Laboratories).
2.10.2 Calculation and interpretation
The data were analyzed and the concentration of each cytokine was calculated using 
Bio-Plex Manager Software. The units for the cytokine levels were pg/ml. The limits 
of detection were 0.23 (IL-ip), 0.84 (IL-2), 0.14 (IL-4), 1.5 (IL-5), 1.23 (IL-6), 0.96 
(IL-10), 0.2 (IL-12p70), 1.19 (IL-13), 0.34 (IFNy), 0.14 (TNFa) and 10 (IP10) (all 
pg/ml).
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2.11 T cell phenotyping
150pl whole blood was mixed with 5pi of antibody cocktail of CD3-APC (BD -  
555342, an antibody against T cells in general), CD4-APC-Cy7 (BD -  341105, an 
antibody against CD4+ T cells), CD8-P (BD -  555367, an antibody against CD8+ T 
cells), CD38-PE-Cy7 (BD -  335808, an antibody against activated T cells) and HLA- 
DR-PerCP (BD -  347364, an antibody against activated T cells) in BD Falcon tubes 
for 10 seconds. This mixture was then incubated at room temperature in the dark for 
20 minutes. 1.5 ml FACS lysing buffer (BD - 349202) was added to the mixture and 
mixed for 10 seconds, then incubated at room temperature in the dark for 10 minutes. 
The assay was continued with centrifugation at 1600 rpm for 5 minutes. The 
supernatant was discarded and the pellet was washed with 2ml of washing buffer (3% 
heat inactivated FCS (Sigma) and ImM EDTA (Merck) in PBS) and resuspended in 
500pl of FACS Perm2 (BD - 340973). This suspension was well mixed for 10 
seconds and then incubated for 10 minutes at room temperature in a dark 
environment. Centrifugation at 1600 rpm for 5 minutes was performed to collect the 
pellet which was subsequently washed with 2ml of washing buffer and incubated with 
intracellular antibody against Ki67-FITC (BD - 51-36524X, an antibody against 
activated T cells) for 15 minutes at room temperature in dark. After washing, 150pl of 
1% Paraformaldehyde (Merck) solution was added to the stained cells for fixation. 
Data were acquired using a FACS Canto flow cytometer (Becton Dickinson) and the 
raw data were analyzed using Cellquest or FlowJo software.
2.12 Expression microarrays
2.12.1 Whole RNA extraction
2.5ml of whole blood which had been stored in Paxgene RNA tubes (Qiagen) was 
used for RNA extraction using Paxgene RNA kits (Qiagen) according to the 
manufacturer’s instructions. In brief, the whole blood was transferred to a 50ml 
Falcon and centrifuged at 3000g for 10 minutes to collect the pellet. After washing 
with 5ml RNase-free water, the pellet was lysed by adding 350pl of BR1 and 300pl of 
BR2 and 40pl proteinase K respectively and incubating on a shaker at 55°C for 10
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minutes. The lysate was then transferred into a PAXgene shredder spin column placed 
in a 2ml processing tube and centrifuged for 3 minutes at maximum speed. The entire 
supernatant of the flow-through fraction was carefully transferred to a fresh 1.5 ml 
centrifuge tube without disturbing the pellet in the processing tube. 350pl of ethanol 
(96-100%) was added and mixed with the solution and then transferred immediately 
into a PAXgene RNA spin column placed in a 2ml processing tube which was then 
centrifuged for 1 minute at 10,000 g and washed with 350pl of BR3. 80pl of DNase I 
incubation mix (lOpl of DNase I stock solution and 70pl Buffer RDD) was directly 
pipetted onto the PAXgene RNA spin column membrane and incubated for 15 
minutes at room temperature. In the next step, 350pl of BR3 was continued to add to 
the column which was then centrifuged for 1 minute at 10,000g. The column was 
washed twice with 500pl of BR4. RNA was eluted from the column by 2 further 
incubations of 40pl of BR5 for 2 minutes with centrifugation for 1 minute at 10,000g. 
The RNA was quantified and qualified using Nanodrop. RNA was kept at minus 80°C 
until use.
The Illumina® TotalPrep™-96 RNA Amplification Kit (Ambion) was used for cRNA 
synthesis and purification according to the manufacturer’s instructions, including the 
following steps (from 2.12.2 - 2.12.4).
2.12.2 Reverse transcription to synthesize first strand cDNA
11 pi of RNA suspension containing about 500ng of RNA was mixed with 9pl of 
reverse transcription master mix (2pl 10X first strand buffer, 4pl of dNTP mix, lpl of 
T7 oligo(dT) primer, lpl of RNase inhibitor and lpl of ArrayScript). The reaction was 
incubated for 2 hours at 42°C. After incubation the tube was centrifuged briefly to 
collect the reaction product at the bottom of the tube.
2.12.3 Second strand cDNA synthesis and purification
The second strand master mix (63pl nuclease-free water, lOpl 10X second strand 
buffer, 4pl dNTP mix, 2pl DNA polymerase and lpl RNase H) was prepared on ice 
and mixed with product from the first strand cDNA synthesis. The reaction was 
incubated at 16°C for 2 hours and then put on ice before cDNA purification.
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180pl of resuspended cDNAPure was added to each second strand cDNA synthesis 
reaction. The mixture was transferred to a U-Bottom Plate and gently shaken for 2 
minutes to thoroughly mix the sample with the cDNAPure. The plate was put onto a 
magnetic stand for about 5 minutes so that the magnetic beads could be captured. 
When the capture was complete, the supernatant was carefully aspirated without 
disturbing the magnetic beads. The plate was removed from the magnetic stand and 
the beads were washed twice with 150pl of cDNA wash buffer and then dried by 
shaking vigorously for 2 min. The cDNA was eluted from the beads by incubating the 
beads with 20pl preheated 55°C nuclease-free water and vigorously shaking for 3 
minutes. cDNA was collected by putting the plate on a magnetic stand for 5 minutes 
and carefully transferring 17.5pl of the supernatant into the wells of a new PCR plate.
2.12.4 In vitro transcription (IVT) to synthesize anti-sense RNA and purification
7.5pl of IVT master mix (2.5ul Biotin-NTP mix, 2.5pl T7 10X reaction buffer, 2.5pl 
T7 enzyme mix) was added and gently mixed with each sample (purified cDNA). The 
reaction was incubated at 4°C in the dark overnight. Each tube of cRNA product was 
mixed with 70pl cRNA Binding Mix and 95pl of absolute ethanol. The mixture was 
transferred to a U-Bottom Plate and shaken vigorously for 2 minutes. The plate was 
put on the magnetic stand for about 5 minutes until the magnetic beads were 
completely captured, then the supernatant was carefully aspirated without disturbing 
the magnetic beads. The plate was removed from the magnetic stand and the magnetic 
beads were washed twice with lOOpl of cRNA Wash Solution. After the magnetic 
beads had been dried by vigorously by shaking the plate for 1 minute, purified cRNA 
was eluted by adding 40-1 OOpl of preheated (55°C) cRNA Elution Buffer to each 
sample and shaking vigorously for 3 minutes. The supernatant containing cRNA was 
collected and transferred to a nuclease-free PCR plate, then kept at -80°C until use.
2.12.5 Array hybridization
The Direct Hybridization assay in this step was carried out as the instructions from the 
manufacturer. Briefly, for each sample 2jig of cRNA in 5pi of RNase-free water was 
heated at 65°C for 5 minutes and cooled at room temperature before being mixed with 
lOpl of Hyb which had been previously heated at 58°C for 10 minutes. The samples
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were loaded onto the BeadChip (Human HT-12 v4.0). The Hyb Chamber Insert 
containing sample-laden BeadChips was loaded into each Hyb Chamber, which was 
incubated in a preheated oven at 55°C for 20 hours. The assay was continued with 
these washing steps; the chip was washed firstly in IX High-Temp Wash buffer 
which was preheated at 55°C in Hybex Waterbath for 10 minutes, and then in Wash 
E1BC solution for about 5 minutes on an orbital shaker. The rack containing the 
BeadChip was transferred to a staining dish containing absolute Ethanol and 
incubated there for 10 minutes on the orbital shaker. It was then returned to the Wash 
E1BC solution for another 2 minutes on the orbital shaker. After the washing, the 
BeadChip was blocked with 4ml Block El buffer for 10 minutes and stained with 2ml 
of streptavidine-Cy3 in Block El buffer for 10 minutes and then washed with Wash 
E1BC for 5 minutes. The BeadChip was dried by centrifugation at 1,400 rpm for 4 
minutes. The BeadChip was scanned on the Illumina BeadArray Reader. From there 
the gene expression data were extracted.
2.13 Quantitative RT-PCR (qRT-PCR) validation
2.13.1 Reverse transcription
cDNA was synthesized from RNA using High Capacity cDNA Reverse Transcription 
Kits (Applied Biosystems) following the manufacturer’s instructions. First 500ng of 
RNA in 10 pi of RNase-free water was added to 10 pi of 2X-reverse transcription 
master mix. The reaction was loaded to the thermal cycler and incubated at 25°C for 
10 minutes, 37°C for 120 minutes, and 85°C for 5 minutes.
2.13.2 Pre-amplification
Taqman assays which are the sets of primers and probes for the 31 genes of interest, 
and 18S as a house keeping gene, were prepared by mixing them together with equal 
ratio. 1.25pl of cDNA was added to 3.75pl of master mix for pre-amplification (2.5pl 
of Taqman Preamp master mix (2X) and 1.25pl of pooled assay mix (0.2X)). The 
reaction was loaded to the thermal cycler and run under the following conditions: 
95°C for 10 minutes and then 14 cycles of 95°C for 15 seconds and 60°C for 4 
minutes.
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2.13.3 Amplification
The 48.48 Dynamic Array™ FC (Fluidigm) was used for the realtime RT-PCR 
following the instructions of the manufacturer. First the fluidigm was primed with 
control line fluid in an Integrated Fluidic Circuit (IFC) Controller MX machine. Next, 
the lOx Taqman assays (5pl: 2.5pi of 20X Taqman Gene Expression and 2.5pl of 2X 
Assay Loading Reagent) and mixture of sample and amplification premix (2.5pl of 
Taqman Universal PCR Master Mix, 0.25pi of DA Sample loading reagent, 2.25pl of 
1:5 diluted Pre-amplification product) were added to the chips. The micro fluidic chip 
was then run in the BioMark instrument (BioMark). PCR results were collected and 
verified using the BioMark Data Collection software and the BioMark Real-Time 
PCR Analysis software.
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Chapter 3
DEVELOPING ALGORITHMS TO DIFFERENTIATE PRIMARY 
FROM SECONDARY DENGUE VIRUS INFECTIONS
3.1 Introduction
As discussed in the introductory chapter, immune status is considered to be an important 
factor contributing to dengue pathogenesis. Currently, a number, of methods are used to 
differentiate primary from secondary dengue. Previously HI was recommended as the gold 
standard for this purpose; however several relatively complicated preparatory steps are 
needed and the test is time-consuming to conduct. Also HI fails to discriminate between 
infections by closely related flaviviruses, such as Japanese encephalitis virus (JEV). Another 
disadvantage is that paired samples are required for a reliable result -  i.e. acute and 
convalescent samples -  and in clinical practice the second sample is frequently not obtained 
as the patient has already recovered. PRNT is another method used to define dengue immune 
status. Although rather cumbersome and time consuming to perform, the neutralization assay 
is considered to be the serological technique with the greatest specificity, allowing 
differentiation from other flaviviruses as well as determination of neutralizing antibody levels 
to the four dengue serotypes. However, since the specificity of neutralizing antibodies 
increases over time, samples for PRNT are best collected in late convalescence in order to 
avoid cross-reactive responses, i.e. several months or years after recovery. This is not 
practical or useful in the clinical context, and it can also be a problem in research studies, as it 
can be difficult to keep track of study participants especially in dengue endemic areas.
In comparison to both HI and PRNT, serological testing using ELISA techniques to measure 
IgM and/or IgG is simpler, cheaper, and requires less training for laboratory staff; thus these 
techniques can be applied to much larger numbers of samples. Innis defined a case as a 
primary infection if the IgM/IgG ratio was greater than 1.78 or as a secondary infection if the 
ratio was below this level [125]. Shu used a similar technique with IgM/IgG ratios but with a 
different cutoff, 1.2, while Kuno used the cut-off of 1.4 [126, 127]. The problem with these 
algorithms is that they do not account for the well-established evolution of antibody kinetics 
during acute infections. In some studies, a combination of the two cutoffs has been used, i.e.
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a case was defined as primary if the IgM/IgG ratio was above 1.78, secondary if the IgM/IgG 
ratio was under 1.2 and unidentifiable if the ratio was in between [158]. This combined 
algorithm may be more relevant because it, to a certain degree, takes into account the 
evolving antibody response; however a proportion of cases where the ratio falls between the 
two cutoffs cannot be classified. Other algorithms have used IgM/IgG ratios with paired 
samples, IgG titers, and IgG avidity, but all these methods have issues related to 
inconvenience with sampling and/or complicated methodology [112, 128,159, 160]. Another 
disadvantage of algorithms based on IgM/IgG ratios is that typically they rely on in-house 
assays and these tend to be quite variable, especially between different laboratories. In 2009, 
Cordeiro developed an algorithm based on a commercial kit (Panbio Capture IgG) with 
cutoffs depending on the day of illness [129]. However, the number of samples included on 
each day of illness was small. Also the model used a combination of virology and serology 
results as the gold standard to discriminate primary from secondary dengue, including the 
Panbio Capture IgG which was later used as the main parameter in the model.
3.2 Purpose of the study
The aim of this study was to develop models suitable to distinguish primary from secondary 
dengue with high accuracy using serological data from single specimens obtained on any day 
of illness during the acute phase.
3.3 Materials and Methods
3.3.1 Recruitment sites
The main site for patient recruitment for the studies described was the Hospital for Tropical 
Diseases (HTD) in Ho Chi Minh City. This is the referral hospital for infectious diseases for 
southern Vietnam and serves a catchment population of 38 million people, under the direction 
of the Ministry of Health of Vietnam. HTD has 21 clinical and ancillary departments with 
about 500 beds. HTD is the founding partner and host of the Oxford University Clinical 
Research Unit, where I am doing my PhD programme. Some patients were also recruited 
from a community clinic operating in District 8 of the city. This clinic is run by an 
experienced physician who also has a position at HTD and has been involved with clinical 
studies about dengue for more than 10 years.
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3.3.2 Study population
All confirmed dengue patients (aged 5-25 years old) who had been/were enrolled into one of 
our ongoing dengue studies in Ho Chi Minh City, Vietnam (Table 3-1) within the six months 
prior to the start of this study in 2010 up to the study closure in 2013, were contacted and 
asked to join this study and attend a follow-up visit approximately 6 months after the acute 
illness. All the acute dengue studies had been carried out with appropriate local and 
international IRB approvals, and the protocol for this study was approved by the Ethical 
Committee of HTD and the Oxford Tropical Research Ethics Committee. Following written 
consent by the patient or the patient’s parent/guardian a short questionnaire was completed 
and a 2 ml blood sample was taken if the subject had been well during the intervening time. 
In the majority of the primary studies from which these subjects were recruited the patients 
had been enrolled within 72hrs of fever onset, except for one hospital based study (Study 3) 
when patients were enrolled up to day 5 of illness [36, 44]. All participants had been 
reviewed daily from study enrolment until afebrile for 2 consecutive days, or discharge in 
cases of hospitalization, with detailed clinical information recorded and, as a minimum, a 1ml 
blood sample was obtained at each visit for a complete blood count with the residual plasma 
saved for research. Additional blood samples were obtained for other tests according to the 
individual study protocols. The day of illness was counted as 1 from the reported day of 
fever onset (Day 1, Day2, Day3 etc).
3.3.3 Laboratory methods
The laboratory methods used for the daily acute illness specimens are described in Chapter 2 
(Materials and Methods), including methods for the two-step realtime RT-PCR, Panbio IgG 
Indirect ELISA, in-house anti-E protein IgG indirect ELISA and in-house IgM and IgG 
capture ELIS As. Convalescent samples obtained at around 6 months were sent to the US for 
PRNTs at the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious 
Diseases, NIH; a brief description of the methods used there is also presented in Chapter 2. 
For this work I used PRNT60 titers -  i.e. the reciprocal of the dilution at which the number of 
plaques was reduced by 60%. For convenience, in this chapter I will refer to the serotype 
causing the recent infection as the “current” serotype when discussing the PRNT60 values six 
months later, while all remaining serotypes will be referred to as “other” serotypes.
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3.3.4 Statistical analysis
Continuous variables are presented as median (inter-quartile range, IQR) while categorical 
variables are presented as frequency (%) throughout. Continuous variables with right-skewed 
distributions were log2-transformed prior to the analysis. Univariate logistic regression was 
used to investigate associations between demographic characteristics and clinical parameters 
on enrolment day, and immune status as defined by the PRNTs.
Table 3-1: The dengue studies from which the patients were recruited
Study Description of primary study
Number of patients recruited 
for 6 month follow-up*** 
(2010-2013)
1
Community based descriptive study of children 
with suspected dengue -  2005-2009 
Participants: children aged from 5-15 years.
23(0)
2
Hospital based clinical trial of early steroid 
therapy for dengue -  2008-2010 
Participants: patients aged from 5-20 years
127 (N/A)
3
Hospital based descriptive study of adults with 
suspected dengue -  2009-2011 
Participants: patients aged from 19-25 years
9 (N/A)
4
Community based study focused on diagnosis 
and risk prediction in early dengue -  2011 
onwards
144 (21)
* The numbers represent the total number o f participants recruitedfrom each study, and in 
brackets, fo r the community-based studies, the number o f  the subjects who were hospitalized.
Only cases with clearly defined immune status according to the PRNTs were included in the 
development of the diagnostic algorithms. First I developed “all-inclusive” models, aiming to 
incorporate data from all available samples from Day2 -  Day7 and to develop a unified 
algorithm which can determine the immune status based on a single sample from any of these 
days. The “all-inclusive” models were based on logistic regression with immune status as the 
outcome, and the (log2 transformed) marker value and the day of illness as predictors. In 
order to take into account potential dependency between samples from the same patient, 
marginal logistic regression was used and parameters estimated based on generalized 
estimating equations and an independence working correlation structure. One model was
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developed for each of the following parameters - Panbio Indirect IgG, in-house anti-E 
indirect IgG, in-house capture IgM, in-house capture IgG, and in-house capture IgM/IgG 
ratio. Within each all-inclusive model the cutoff point for that parameter was taken as the 
point where the probability of differentiating primary from secondary dengue achieved the 
maximum accuracy ([true positive + true negative]/total cases). The coefficients relevant to 
that marker for each individual day of illness were then used to calculate the day-specific 
cutoffs with this optimal probability. To be specific, if the logistic model specified a relation 
of the form logit (probability of detecting secondary infection)=a + bl * marker + b2 * day of 
illness, and the optimal cutoff point for the probability was determined as p, then the cutoff 
for the marker on Day2 = [logit(p) - a - b2 * 2] / b l, the cutoff for the marker on Day3 = 
[logit(p) - a - b 2 * 3 ] / b l ,  and so on for each successive day.
Potential interactions between marker levels and day of illness, non-linearity of marker 
effects (modeled as flexible natural cubic spline functions with 4 degrees of freedom), or 
effect of other covariates (sex, age, serotype, hospitalization) were assessed using Wald-type 
tests.
The resulting all-inclusive models were validated using bootstrapping and temporal 
validation. Bootstrap validation was implemented as described in Harrell, Chapter 5.2.5 
[161]. Specifically, I repeatedly fitted the models to 1000 bootstrapped datasets and evaluated 
them on the original dataset to estimate the “optimism”, i.e. the amount of over-fitting 
obtained from fitting and evaluating the model on the same dataset. Subsequently, the 
apparent performance of the models was corrected for this optimism. For temporal validation, 
patients were divided into 5 equal groups by time. I then carried out model development on 
training sets including 4 of these patient groups on each occasion, and validated the model on 
the remaining (5th) group of patients. The final performance was calculated as the average 
performance after 5 times of validation.
The performance of these all-inclusive models was compared to a number of “time-specific” 
models which included only the corresponding marker values obtained on Day3 (early-phase 
models); on Day6 (late-phase models); on both Day3 plus Day6 jointly (dual-phase models); 
and all days from Day3 to Day6 jointly (Day3-6 models) using univariate or multivariable 
logistic regression. Accuracy, area under the ROC curve (AUC), specificity, sensitivity, 
positive predictive value and negative predictive value were used in assessing and comparing
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the performance of the models. In addition, several of the algorithms currently in use were 
assessed using this dataset [125, 127].
All statistical analyses were performed with the statistical software R version 3.1.1 
(07/10/2014) [162].. Marginal logistic regression models were fitted with the companion R 
package geepack version 1.2-0 [163].
3.4 Results
3.4.1 PRNT results and discrimination of primary from secondary dengue
A total of 303 patients with confirmed dengue who participated in one of our acute dengue 
studies, agreed to join this study between May 2010 and July 2013. All the study participants 
had been well in the intervening time since their acute illness. The median time to this late 
convalescent visit when the samples for the PRNT assays were obtained, was 212 (IQR: 188- 
239) days since fever onset.
The PRNT60 titer against the current serotype was not always the highest of the values 
measured at this time. In general the PRNT60 titers against DENV1 were higher than the titers 
against the other serotypes. There were 4 main patterns that I observed: i) pattern 1 -  high 
PRNT60 titer against the current serotype with negative PRNT60 titers against all other 
serotypes, using the conventional cutoff of 10; ii) pattern 2 -  high PRNT60 titers against at 
least 2 serotypes, including the current serotype; iii) pattern 3 -  PRNT60 titer below 10 for the 
current serotype with variable responses to the other serotypes; and iv) pattern 4 -  similar and 
low PRNT60 titer (around 20) for the current serotype and one or more of the other serotypes. 
Although defining immune status for patients with patterns 1 and 2 was straightforward this 
was more difficult for patterns 3 and 4. In consultation with Dr Whitehead from NIH, I 
decided on the system presented in Table 3-2, and accepted that not all patients could be 
classified. First, in all cases a response to the current serotype (as identified by RT_PCR 
during the acute illness) should be clear, with a PRNT60 value > 20 documented. If  no 
response was measurable to this serotype the immune status was automatically classified as 
unknown. Infections were then defined as primary if the PRNT60 titers against all other 
serotypes were <20, or as secondary if the PRNT60 titer against at least one other serotype 
was >40 or >PRNT6o titer of the current serotype. All other cases were defined as unknown 
immune status.
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Table 3-2: Rule for defining immune status based on PRNT60 results
PRNT60 titers against:
Immune status Current serotype Other serotypes
Primary >20 all < 20
Secondary >20 at least one other > 40 or > the titer for the current serotype
<20 -
Unknown
> 20 all < 40 and < current serotype’s PRNT60 titer, but not all <20
Based on these definitions, 105/303 patients (35%) were defined as having primary infections 
and 144 patients (48%) were defined as having secondary infections. The remaining 54 
patients (17%) could not be classified; in 24 patients the PRNT60 to the current serotype was 
below the threshold of 20; in 20 cases with an acceptable response to the current serotype, the 
PRNT60 values for the other serotypes did not fit the definition for a secondary response; 9 
patients with serologically confirmed dengue were found not to have had the serotype 
identified by RT-PCR during the acute illness; and in 1 case the PRNT60 results were 
missing. These data are summarized in Error! Reference source not found..
3.4.2 Patient characteristics and associations with immune status
The majority of the patients enrolled in this project were recruited from 2 of our acute dengue 
studies, as indicated in Table 3-1. A) Study 2 - the hospital based trial of early prednisolone 
therapy that ran from 2008 to 2010. Enrolment was limited to subjects with less than 72 hours 
of fever, and generally occurred within the first 24 hours after hospitalization. No difference 
was detected in the IgM and IgG levels across the three treatment arms in the trial [164]. B) 
Study 4 - a community based study focused on diagnosis and risk prediction in early dengue 
that commenced in 2011 and is still in progress. This study also enrolled within 72 hours of 
fever onset. Although enrolled as outpatients, participants in this study can be hospitalized if 
for any reason the treating physician considers this necessary, and a total of 21 patients 
included in this sub-study were hospitalized.
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Chapter 3
Patient characteristics for the subjects with primary, secondary and unknown immune 
status are presented in Table 3-3. Using univariate logistic regression, older age and 
female sex were more likely to be associated with secondary dengue, with odds ratios 
(OR) of 1.11 (95% confidence interval [95% Cl]: 1.05 -  1.17) for each +1 year 
increase in age and 2.79 (1.61 -  4.83) for female gender, respectively. However, there 
was no significant difference in age between male and female patients. In addition, 
infections with DENV2 and DENV4 were more likely to be secondary than were 
DENV1 infections, with OR (95% Cl) for DENV2 and DENV4 compared to DENV1 
of 3.03 (1.57 - 5.84) and 16.36 (4.79 - 55.88) respectively. Patients with secondary 
dengue seemed to present later than those with primary infections, though the day of 
illness at presentation was not significantly associated with immune status (p=0 .1 , 
logistic regression). Surprisingly, patients with secondary dengue were less likely to 
be hospitalized (OR (95% Cl): 0.49 (0.29 -  0.82). However this finding likely reflects 
demographic differences in the different study populations; thus patients in the 
community studies (mainly Study 4) were more likely to be older than patients in the 
hospital based studies (mainly Study 2) with a median (IQR) age of 15 (12, 20) years 
compared to 12 (10, 14) years). Thus a higher proportion of secondary dengue was 
seen among community participants compared to patients who were hospitalized at 
any time (67% versus 50%). Considering Study 2 only, being female, older, and 
having either a DENV2 or DENV4 infection (compared to DENY1) was more likely 
to be associated with secondary dengue. When assessing Study 4 alone the results 
were similar, except that later enrolment was also significantly associated with 
secondary dengue.
IgM and IgG levels from the day of enrolment (Day2 or Day3 in 93% of cases) are 
summarized in Table 3-4. IgG but not IgM levels were significantly higher in 
secondary than in primary dengue, after adjustment for the day of illness at enrolment. 
The kinetics of the antibody responses by day of illness are shown in Figure 3-2, for 
all three immune status groups. IgG levels started to rise earlier and peaked at a higher 
level in secondary than primary dengue while IgM kinetics were quite similar 
between primary and secondary infections. The responses observed in those with
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indeterminate immune status were more similar to the secondary than the primary 
responses.
Table 3-3: Patient characteristics
Primary Secondary Unknown*
N=105 N=144 N=54 p value
(35%) (48%) (17%)
Age (years) 13 (10.0-16.0) 14(11.0-19.0) 14(12.0- < 0 . 0 0 1
Sex (male) 79 (75) 76 (53) 42 (78) < 0 . 0 0 1
1 6 (6 ) •5 (4) 6 ( 1 1 )
U
> §
2 51 (49) 54 (38) 23 (43)
*8 5 3 45 (43) 82 (57) 25 (46) 0 . 1
© u 4 2 (2 ) 3(2) 0 (0 )
Q 5 1 (1 ) 0 (0 ) 0 (0 )
1 75 (71) 55 (38) 8(18)
a 2 18(17) 40 (28) 18(40)
< 0 . 0 0 1oShVVI
3 9(9) 13(9) 7(15)
4 3(3) 36 (25) 12 (27)
Continuous variables are presented as median (IQR) and categorical variables are 
presented as number and frequency. P values are from comparisons between 
primary and secondary infections, using univariate logistic regression.
(*) There were 9 cases with unknown serotypes
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Table 3-4: IgM and IgG levels at enrolment
Parameter
Primary*1*
N=104
Secondary*2*
N=135
Unknown*3*
N=51
P
value
Panbio Indirect IgG
(Panbio unit)
2 . 2  
(1 .1  - 1 1 .0 )
38
(24.8 - 49.5)
33.5 
(9.8 - 45.9)
<0 . 0 0 1
In-house anti-E indirect IgG
(index unit)
2 . 1  
(1.2-3.4)
6.3 
(3.1 - 15.5)
5.8 
(2.6 -16.4)
<0 . 0 0 1
In-house capture IgG
(index unit)
1.3 
(0.5-1.9)
6 . 2
(3.3-11.6)
4.7
(1.4-11.7)
<0 . 0 0 1
In-house capture IgM
(index unit)
4
(2.7 - 5.9)
4.8 
(3.7 - 7.0)
4.6 
(3.9 - 6.7)
0.5
P values relate to comparisons between primary and secondary dengue, using logistic 
regression adjusted for day o f illness at enrolment. (1)1, (2) 9, and (3) 3 cases did 
not have results for these parameters on the enrolment day.
3.4.3 All-inclusive models
Values for the different parameters obtained from Day2 to Day7 (541 and 673 
samples from 105 primary and 144 secondary infections, respectively) were used to 
develop the all-inclusive models. The all-inclusive model based on the Panbio Indirect 
IgG gave the best performance compared to the other models (Table 3-5). When 
evaluated separately by illness day, the performance of the all-inclusive model for 
Panbio Indirect IgG proved to be better in the early phase rather than the late phase, 
with decreasing accuracy fromDay2 to Day7: 0.87, 0.87, 0.87, 0.85, 0.77, and 0.79.
The performance of the all-inclusive models using the in-house capture IgG and in- 
house capture IgM/IgG ratio were also good, although again with variable 
performance throughout the illness course (Table 3-5). However, as expected the 
model based on in-house capture IgM values was not suitable to differentiate primary 
from secondary dengue with an accuracy of only 0.58.
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Table 3-5: Performance of the all-inclusive models to discriminate primary from 
secondary dengue
Marker AUC (95% Cl) Accuracy Sens. Spec. PPV NPV
Panbio Indirect IgG 0.90 (0.88 - 0.92) 0.85 0.91 0.78 0.84 0 . 8 6
In-house anti-E indirect IgG 0.80 (0.78 - 0.83) 0.76 0.78 0.74 0.80 0.72
In-house capture IgG 0.86 (0.83 - 0.89) 0.84 0.89 0.77 0.84 0.84
In-house capture IgM 0.55 (0.51 - 0.59) 0.58 0.81 0.28 0.60 0.53
In-house capture IgM/IgG ratio 0.88 (0.85 - 0.90) 0.84 0.90 0.77 0.83 0.85
(*) The all-inclusive models were developed using marginal regression, clustered by patient, 
with the following formula: Logit (secondary/primary) = Marker + DOI
For this and subsequent similar tables in this chapter AUC: area under ROC curve; Sens: 
sensitivity; Spec.: specificity; PPV: positive predictive value; NPV: negative predictive value 
Cutoff was selected to maximize accuracy as described in the statistical methods section.
Using a Wald-type test, an interaction term between marker level and day of illness 
was shown to have a significant effect in all the all-inclusive models (all p values < 
0.001), except for the model based on the in-house capture IgG where the result was 
borderline (p=0.07). However, the general performance of the various models with or 
without interaction was comparable, except for the model using the Panbio Indirect 
IgG. In this instance although the general performance of the two models with and 
without the interaction was comparable, the performance of the model with the 
interaction was much better on Day6  (accuracy of 0.77 and 0.84 for non-interaction 
and interaction models respectively). Adjustment for other covariates (sex, age, 
serotype, hospitalization and time of sampling), or including the marker in a flexible, 
potentially non-linear way, both statistically significantly improved on the all- 
inclusive models (all p values < 0.001 for Wald-type comparison of the more flexible 
models to the basic all-inclusive models), but the performance of the models changed 
very little (Table 3-6).
Taking into account these effects, I decided to choose linear models including the 
marker (modeled as a linear term) and the day of illness (but no further adjustment)
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for the in-house anti-E indirect IgG, the in-house capture IgG and the in-house capture 
IgM/IgG ratio for all subsequent analyses. The same approach was used for the 
Panbio Indirect IgG but an additional interaction term between the marker and the day 
of illness was included, which was also used for all subsequent analyses. The 
performance of the selected all-inclusive models for each individual day from Day2 to 
Day7 is summarized in Table 3-7.
Table 3-6: Performance of all-inclusive models, adjusted for interactions with 
day of illness, significant covariates, and non-linearity
Marker
Performance
AUC 
(95% Cl) Accuracy Sens. Spec. PPV NPV
All-inclusive models with interaction with day of i Iness
Panbio Indirect IgG 0.90 (0.88 - 0.92) 0.84 0.89 0.76 0.82 0.85
In-house anti-E indirect IgG 0.82 (0.80 - 0.85) 0.76 0 . 8 6 0.64 0.75 0.78
In-house capture IgG 0.88(0.86-0.90) 0.83 0.90 0.75 0.82 0 . 8 6
In-house capture IgM/IgG ratio 0.89 (0.87 - 0.91) 0.83 0 . 8 6 0.78 0.83 0.82
All-inclusive models adjusted for the covariates ^
Panbio Indirect IgG 0.90 (0.89 - 0.92) 0.83 0.90 0.75 0.82 0 . 8 6
In-house anti-E indirect IgG 0.83 (0.81 - 0.85) 0.76 0.80 0.71 0.77 0.74
In-house capture IgG 0.89 (0.87 - 0.91) 0.83 0.90 0.74 0.81 0 . 8 6
In-house capture IgM/IgG ratio 0.89 (0.88 - 0.91) 0.83 0.85 0.81 0.84 0.81
All-inclusive models adjusted for non-linearity
Panbio Indirect IgG 0.89 (0.87 - 0.91) 0.84 0.92 0.74 0.81 0 . 8 8
In-house anti-E indirect IgG 0.79 (0.76 - 0.82) 0.74 0.76 0.71 0.77 0.71
In-house capture IgG 0.86 (0.84 - 0.88) 0.82 0.90 0.74 0.81 0.85
In-house capture IgM/IgG ratio 0.88 (0.86 - 0.90) 0.83 0.87 0.78 0.83 0.83
(*): the all-inclusive models were adjusted for sex, age, serotype, hospitalization and time o f  
sampling
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Table 3-7: Performance of the all-inclusive models on each individual day of 
illness, from Day2 to Day7
Performance
Accuracy Sens. Spec. PPV NPV
Day2 (56 primary vs 55 secondaryV dengue)
Panbio Indirect IgG 0 . 8 6 0.91 0.80 0.82 0.90
In-house anti-E indirect IgG 0.71 0.75 0 . 6 8 0.70 0.73
In-house capture IgG 0.76 0.87 0.64 0.71 0.84
In-house capture IgM/IgG ratio 0.80 0.78 0.82 0.81 0.79
Day3 (102 primary vs 135 secondary dengue)
Panbio Indirect IgG 0 . 8 6 0 . 8 6 0 . 8 6 0.89 0.82
In-house anti-E indirect IgG 0.77 0.73 0.82 0.85 0.69
In-house capture IgG 0.83 0.81 0.85 0 . 8 8 0.77
In-house capture IgM/IgG ratio 0.80 0.79 0.80 0.84 0.75
Day4 (102 primary vs 136 secondary dengue)
Panbio Indirect IgG 0 . 8 6 0 . 8 6 0.90 0.80 0.85
In-house anti-E indirect IgG 0.79 0.79 0.79 0.84 0.74
In-house capture IgG 0.85 0.89 0.80 0 . 8 6 0.85
In-house capture IgM/IgG ratio 0.82 0.87 0.77 0.83 0.81
Day5 (101 primary vs 140 secondary dengue)
Panbio Indirect IgG 0.87 0.94 0.77 0.85 0.90
In-house anti-E indirect IgG 0.78 0.83 0.71 0.80 0.75
In-house capture IgG 0.85 0.94 0.73 0.83 0.89
In-house capture IgM/IgG ratio 0 . 8 6 0.89 0.81 0.87 0.84
Day6 (98 primary vs 116 secondary dengue)
Panbio Indirect IgG 0.84 0.93 0.72 0.80 0.90
In-house anti-E indirect IgG 0.71 0.79 0.61 0.71 0.71
In-house capture IgG 0.81 0.94 0 . 6 6 0.77 0.90
In-house capture IgM/IgG ratio 0.85 0.91 0.79 0.83 0 . 8 8
Day7 (82 primary vs 91 secondary dengue)
Panbio Indirect IgG 0.79 0.74 0.84 0.84 0.74
In-house anti-E indirect IgG 0.64 0.65 0.62 0 . 6 6 0.61
In-house capture IgG 0.80 0.93 0 . 6 6 0.75 0.90
In-house capture IgM/IgG ratio 0.83 0.96 0 . 6 8 0.77 0.93
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The cutoffs for each parameter on each individual day, as derived from the all- 
inclusive models, are presented in Table 3-8. For the Panbio Indirect IgG, the in- 
house anti-E indirect IgG, and the in-house capture IgG, an infection would be 
defined as secondary if the value equals or exceeds the cutoff for that day, while for 
the capture IgM/IgG ratio an infection would be defined as secondary if the ratio falls 
below the cutoff for that day.
Table 3-8: Cutoffs for the selected parameters, derived from the all-inclusive 
models on each individual day of illness
Day of 
illness
Panbio 
indirect IgG
(Panbio unit)
In-house anti-E 
indirect IgG
(Index unit)
In-house 
capture IgG
(Index unit)
In-house capture 
IgM/IgG ratio
2 9.3 3.0 1 . 6 1 . 8
3 19 4.0 3.1 1 . 6
4 28 5.3 6 . 1 1.4
5 37 7.1 1 2 1.3
6 46 1 0 24 1 .1
7 53 13 47 1 . 0
To assess consistency in defining immune status in individuals over time I first used 
data from all the samples from Day2 to Day7, and found that for 81%, 69%, 72%, and 
71% of the 303 patients the results remained the same throughout the acute illness for 
the Panbio Indirect IgG, in-house anti-E indirect IgG, in-house capture IgG, and in- 
house capture IgM/IgG ratio respectively. As would be expected consistency was 
better if the analysis was restricted to the time when the individual models 
demonstrated good performance; thus the daily results agreed in 262/303 (87%) of 
individuals between Day2 to Day5 for the all-inclusive model based on Panbio 
Indirect IgG, and in 260/301 (8 6 %) and 258/301 (8 6 %) of individuals for the all- 
inclusive models based on the in-house capture IgG and in-house capture IgM/IgG 
ratio respectively when assessed later, between Day4 and Day7. Consistency within 
the time associated with good performance was also better in cases defined by the 
PRNT data as secondary (122/144, 85%); (121/143, 85%); (120/143, 84%) than in
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cases defined as primary dengue (73/105, 70%); (59/105, 56%); (65/105, 62%) for the 
all inclusive models based on Panbio Indirect IgG, in-house capture IgG and in-house 
capture IgM/IgG ratio respectively.
3.4.4 Validation
In order to validate these all-inclusive models, I applied both internal validation using 
bootstrapping, and temporal validation. For the latter method, there were 50 patients 
in each group, except one having 49 patients. The performance in terms of the AUC, 
accuracy, sensitivity, specificity, PPV and NPV of all the models using both 
validation methods was very similar to the performance of the models during the 
development process (Table 3-9), indicating that the models were not over-optimized 
or over-fitted.
Table 3-9: Validation of the all-inclusive models
Performance
Accuracy Sens. Spec. PPV NPV
Bootstrapping validation
Panbio Indirect IgG 0.90 0.85 0.93 0.75 0.83
In-house anti-E indirect IgG 0.81 0.76 0.83 0 . 6 6 0.76
In-house capture IgG 0 . 8 6 0.84 0.87 0.80 0.85
In-house capture IgM/IgG ratio 0 . 8 8 0.84 0.90 0.77 0.84
Temporal validation
Panbio Indirect IgG 0.83 0 . 8 8 0.77 0.82 0.85
In-house anti-E indirect IgG 0.72 0.78 0.60 0.72 0.72
In-house capture IgG 0.80 0 . 8 6 0.75 0.80 0.80
In-house capture IgM/IgG ratio 0.82 0 . 8 6 0.78 0.82 0.81
3.4.5 Comparisons with time-specific models
I then compared the performance of the all-inclusive models with the corresponding 
time-specific models: early-phase, late-phase, dual-phase and Day3-6 models (Table 
3-10).
60
Chapter 3
Table 3-10: Performance of early-phase, late-phase, dual-phase and Day3-6 
models
Performance
AUC 
(95% Cl) Accuracy Sens. Spec. PPV NPV
Early-phase models (102 primary vs 135 secondary dengue)
Panbio Indirect IgG 0.89 (0.84 - 0.93) 0.87 0.91 0.82 0.87 0 . 8 8
In-house anti-E indirect IgG 0.81 (0.75 - 0.86) 0.77 0.73 0.82 0.84 0.69
In-house capture IgG 0.83 (0.77 - 0.89) 0.83 0.81 0 . 8 6 0.89 0.77
In-house capture IgM/IgG ratio 0.82 (0.76 - 0.88) 0.82 0 . 8 6 0.76 0.83 0.80
Late-phase models (98 primary vs 116 secondary dengue)
Panbio Indirect IgG 0.89 (0.85 - 0.93) 0.85 0.93 0.74 0.81 0.90
In-house anti-E indirect IgG 0.73 (0.67 - 0.80) 0.71 0.82 0.59 0.70 0.73
In-house capture IgG 0.85 (0.80 - 0.91) 0.85 0.92 0.77 0.82 0.89
In-house capture IgM/IgG ratio 0.90 (0.86 - 0.94) 0 . 8 6 0.94 0.77 0.83 0.91
Dual-phase models (95 primary vs 109 secondary dengue)
Panbio Indirect IgG 0.90 (0.86 - 0.94) 0 . 8 6 0.89 0.83 0 . 8 6 0.87
In-house anti-E indirect IgG 0.79 (0.72 - 0.85) 0.74 0.72 0.77 0.78 0.70
In-house capture IgG 0.86 (0.81 -0.92) 0.85 0.91 0.79 0.83 0 . 8 8
In-house capture IgM/IgG ratio 0.90 (0.86 - 0.94) 0 . 8 6 0.93 0.79 0.83 0.90
Days 3-6 models (90 primary vs 102 secondary dengue)
Panbio Indirect IgG 0.92 (0.88 - 0.96) 0 . 8 8 0.92 0.82 0.85 0.90
In-house anti-E indirect IgG 0.82 (0.76 - 0.89) 0.79 0.79 0.79 0.81 0.77
In-house capture IgG 0.89 (0.84 - 0.94) 0 . 8 8 0.91 0.83 0 . 8 6 0.89
In-house capture IgM/IgG ratio 0.93 (0.89 - 0.96) 0 . 8 8 0.95 0.79 0.84 0.93
The performance of the all-inclusive models on Day3 (accuracy of 0.86, 0.77, 0.83, 
and 0.80 for Panbio Indirect IgG, in-house anti-E indirect IgG, in-house capture IgG 
and in-house capture IgM/IgG ratio respectively) and Day6  (accuracy of 0.84, 0.71, 
0.81, and 0.85 respectively) was comparable to the performance of the corresponding 
early-phase (accuracy of 0.87, 0.77, 0.83, and 0.82) and late-phase models (accuracy 
of 0.85, 0.71, 0.85, and 0.86) respectively. The performance of the dual-phase and 
Day3-6 models was a little better (accuracy of 0.86, 0.74, 0.85, and 0.86 for the dual­
phase models and 0.88, 0.79, 0.88 and 0.88 for the Day3-6 models respectively).
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3.4.6 Comparisons with previous algorithms
According to the manufacturer’s instructions, when using the Panbio Indirect IgG 
ELISA kit, an infection is defined as secondary if the Panbio units exceed 40 and 
primary if the unit value is below 40, regardless of the day of illness when the sample 
was obtained. In this study, I found that on Day3, the median Panbio Indirect IgG 
among the secondary dengue group was 39.9 units, i.e. more than 50% of the 
secondary infections as defined by PRNT had a Panbio Indirect IgG level below the 
cut-off at this time. Similarly, on Day4, 25% of secondary dengue cases had a Panbio 
Indirect-IgG level below 40 units. In contrast, 25% and 50% of primary dengue cases 
had a Panbio Indirect IgG level above 40 on Day6  and Day7 respectively.
Table 3-11: Performance of previously published algorithms on the present 
dataset
Algorithm Accuracy Sens. Spec. PPV NPV
General performance
Innis, 1989 0.80 (0.78-0.82) 0.73 0.84 0.73 0.84
Shu, 2003 0.79 (0.77-0.81) 0.80 0.79 0.69 0.87
Combination 0.82 (0.80-0.84) 0.78 0.84 0.73 0.87
Performance on Day3
Innis, 1989 0.76 (0.71-0.81) 0.77 0.76 0.63 0 . 8 6
Shu, 2003 0.74 (0.68-0.79) 0.84 0 . 6 8 0.59 0.89
Combination 0.80 (0.75-0.85) 0.77 0.83 0.72 0 . 8 6
Performance on Day6
Innis, 1989 0.82 (0.77-0.87) 0.69 0.90 0.81 0.83
Shu, 2003 0.84 (0.78-0.88) 0.78 0.87 0.79 0 . 8 6
Combination 0.82 (0.76-0.86) 0.78 0.84 0.75 0 . 8 6
As indicated in Table 3-11, with this present dataset, the algorithms of Innis and Shu 
showed better performance in the late phase (accuracy on Day6  of 0.82 (Innis) and 
0.84 (Shu)) compared to the early phase (accuracy on Day 3 of 0.76 (Innis) and 0.74 
(Shu)). The combined algorithm, i.e the algorithm using both cut-offs of 1.2 and 1.78, 
gave stably good performance in both the early and late phases (accuracy of 0.80 and
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0.82 on Day 3 and Day6  respectively). However 6 % of cases could not be classified 
with this strategy.
3.5 Discussion
Discrimination between primary and secondary dengue is important, especially in 
pathogenesis research, but it is also relevant for epidemiological surveillance, and it 
may have a role in clinical practice to identify and target patients at greater risk of 
developing severe dengue. A number of techniques have been used, with HI and 
PRNT generally considered to provide the gold standard, but over the last 20 years a 
number of different options based on simpler tests have been introduced [125-129, 
158, 165-170]. Although some of these options have been validated against a gold 
standard, to date little attention has been paid to the evolving nature of the immune 
response during infection and the resulting variability in defining immune status 
based on a fixed rule.
In this study I developed various models to define dengue immune status based on 
serological responses during the acute illness phase, using the PRNT responses six 
months later as the gold standard. The dataset is unique in that I was able to follow 
daily serological responses from over 300 acute dengue infections covering all four 
serotypes, albeit with low representation for DENV3. The all-inclusive models using 
the Panbio Indirect IgG, in-house capture IgG, and in-house capture IgM/IgG ratio 
performed well, both in general over the illness course and when derived on any day 
from Day2 to Day7. These ELISA based techniques are much quicker and easier to 
perform than HI or PRNT assays, and based on the results from single acute-phase 
specimens used with the cutoffs derived from the all-inclusive models I was able to 
achieve accuracy of 80-85% in discriminating primary from secondary dengue 
compared to the gold standard. The performance of the all-inclusive models using 
single specimens was comparable to the corresponding time-specific models. 
Although the dual-phase and Days3-6 models were a little better, the cost and 
practical difficulties associated with additional sampling and testing limit the 
relevance of this approach.
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I also assessed the performance of two of the established algorithms using our dataset 
[125, 127], and showed that while performance was good during the late phase 
(accuracy above 80% on Day6 ) there were limitations early in the illness course 
(accuracy of 0.76 and 0.74 on Day3 for Innis’s and Shu’s respectively). One 
explanation may be that although in principle the techniques were similar, i.e. capture 
IgM and IgG ELISAs, all the assays were in-house, so the reagents and the 
experimental conditions would have differed slightly between the laboratories. 
Secondly, most of the samples used to develop the established models were obtained 
later in the illness course. Finally both Innis in 1989 and Shu in 2003 used HI results 
from the same time as the test specimens as the gold standard to define immune status 
-  intrinsic interdependence of serological responses obtained at the same time in an 
evolving immune response is to be expected, and may explain why the accuracy of 
these algorithms was not so good when assessed against a different gold standard that 
was independent of the acute phase response. The combined strategy (which has 
never been formally assessed), using both Innis’ and Shu’s cutoffs of 1.78 and 1.2, 
gave better performance in both early and late phases, which was comparable to the 
performance of the all-inclusive model based on the in-house capture IgM/IgG ratio. 
This is consistent with the findings for the cutoffs derived from the in-house capture 
IgM/IgG all-inclusive model, which ranged from 1.8 on Day2 to 1.0 on Day7. 
However, it must be remembered that using the combined algorithm immune status 
cannot be defined for patients where the IgM/IgG ratio falls between 1.2 and 1.78.
Another point to consider is that although the all-inclusive models based on the in-
house capture IgG and the in-house capture IgM/IgG ratio showed good performance
throughout the illness course, actually the IgM and IgG responses as measured by
capture ELISA did not rise above the threshold for a positive response until after
Day4 in most cases. The reliability of measurements under the positive threshold is
questionable. Previous work assessing the performance of the IgM/IgG ratio in the
early acute phase of dengue also recognized the problem of negative results
(responses below the assay threshold for a positive result) of capture IgM and IgG
ELISAs at this stage [126]. In addition, the recommendation from Panbio for
interpreting their IgG capture ELISA indicates the need for a high cutoff (22) to
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distinguish secondary from primary dengue, with the proviso that this cutoff should 
be applied to late phase specimens obtained between days 6  and 15 of illness.
It is difficult to see that models based on negative results in a capture ELISA, which 
assesses acute antibody responses, would be acceptable for defining immune status. In 
contrast indirect ELISA methodology measures much lower concentrations of dengue 
specific IgG in plasma, which would be present in people previously exposed to 
DENV but not in naive people in the early days of an infection, later rising as the 
acute antibody response is superimposed on pre-existing antibody levels. In line with 
this, the all-inclusive model based on the Panbio Indirect IgG without the interaction 
with day of illness showed very good performance in the early phase, with daily 
cutoffs always above the negative threshold as defined by the manufacturer, but less 
good performance later in the illness course. By the time the acute IgG response to the 
current infection becomes established the range of responses is broad, as seen in 
Figure 3-2, and consequently the ability to discriminate between primary and 
secondary infections is impaired. It is also clear that use of the recommended cut-off 
of 40 for the Panbio Indirect IgG without regard to day of illness at sampling, would 
lead to incorrect interpretation of immune status in many cases. Although the 
interaction term helped to improve the performance of this model, in practice a 
convention where an algorithm based on the Panbio Indirect IgG is recommended for 
early acute specimens, while an algorithm based on capture IgG or IgM/IgG ratios is 
used for late acute specimens is likely to be more generally preferred. Unfortunately 
the performance of the in-house anti-E indirect IgG assay was worse than the Panbio 
Indirect IgG, possibly because the target, i.e. anti-E protein IgG, is present at lower 
concentrations than the Panbio target, anti-whole virus IgG. In-house anti-E indirect 
IgG levels rose above the assay positive threshold later than the corresponding Panbio 
anti-whole virus IgG levels, and by this time the influence of the superimposed acute 
response obscured differences between the immune status groups.
Several potential limitations to this study need to be considered. Firstly, I developed a 
large number of different models using this dataset. Sample size estimation is not 
feasible for this kind of study but in the main analysis I included almost 250
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individual patient sample sets, comprising daily acute specimens for an average of 5 
days each, making this the largest assessment of its kind to date. I also planned all the 
statistical analyses in advance, with the main focus on the all-inclusive models, and 
included validation using bootstrapping and temporal validation to show that the 
reported models did not over-fit the data or lead to over-optimistic performance 
claims. One reason for the large number of models is that I wanted to develop 
algorithms based on both in-house and commercial assays. In-house tests are routinely 
used in our laboratory as very large numbers of specimens are processed each year; 
thus, I wished to develop practical tools based on our in-house capture IgG ELISA 
and/or the capture IgM/IgG ratio to apply to our extensive datasets. However, given 
the general limitations of algorithms based on in-house assays, where variability in 
assay performance is to be expected between laboratories and over time, commercial 
kits that employ standardized reagents and methodology (but are much more 
expensive than in-house assays), are preferred when there are no financial constraints. 
Therefore I included assessment of the commercial Panbio Indirect IgG kit, aiming to 
develop a model that could be applied more widely for dengue studies in other 
settings using standardized methodology. Although I would have liked to also assess 
the Panbio Capture IgG and their commercial IgM/IgG ratio this was not possible 
within the available budget.
Secondly, I used PRNTs as the gold standard for developing the models, not HI as has
been used typically in previous studies. One reason for this choice was to try to avoid
circularity -  i.e. use of the same samples collected at the same time point both for
developing the diagnostic algorithms and for the gold standard (HI) assays. In
addition, cross-reactivity is an issue for all serological tests for dengue, and in fact the
neutralization assay is considered to be the serological technique with the greatest
specificity if performed in late convalescence, which could differentiate flavivirus
infections (in review of Maeda [171]). In one specific study the neutralizing antibody
level against DENV was not influenced by previous vaccination against YFV and
JEV [172]. So, by doing the PRNT assays 6  months after the acute illness I tried to
minimize the effect of cross-reactive responses elicited during the acute phase.
However, although unlikely, occurrence of an asymptomatic dengue infection during
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this time in some cases is possible. Several groups have reported variability in the 
results of PRNT assays, influenced by a number of factors such as the virus strains 
used or the passage number, the cell lines, and/or the methods used to fit models [173, 
174]. In this study, the PRNT assays were all performed in the NIH laboratory of Dr 
Whitehead, where this technique is regularly performed and standardized. Studies 
performed in the same laboratory have shown clear differences in responses between 
subjects immunized with candidate vaccines active against one or more serotypes 
[124]. Thus I am confident that the technical aspects of the assays were well executed. 
The 6 -month PRNT data were clear with primary infections, but rather complicated to 
interpret for secondary infections. Given the established cross-reactivity between 
different serotypes a broad range of responses is to be expected in a population living 
in an endemic area that may have had multiple exposures. By setting the cutoffs as I 
did I was conservative about our “gold standard”, although this did result in exclusion 
of 17% of cases from the main analysis. In the 54 patients that were excluded from 
analysis, the proportion of DENV2, DENV3 and DENV4 infections was higher than 
DENV1. One possible explanation may be that the virus strains used in the PRNT 
assay were dissimilar to the strains that are currently circulating in southern Vietnam. 
This might lead to a bias in the PRNT results, potentially with higher PRNT titers 
against DENV1 compared to other serotypes, and as a consequence more DENV2, 
DENV3 and DENV4 infections would be excluded from the analysis. Although a bias 
of this nature might affect the performance of the all-inclusive models, applying the 
all-inclusive models to the acute specimens from this “indeterminate” group of 54 
patients resulted in the majority (70% - 74%) being classified as secondary infections, 
which is in agreement with visual inspection of the plots for the various markers by 
day shown in Figure 3-2. In addition, using the models to define immune status for all 
303 patients who participated in the study showed that 59% -  63% were classified as 
secondary dengue, which is a very similar proportion to the 144/249 (59%) classified 
as secondary dengue based only on the 6  month PRNT data, suggesting that the 
“indeterminate” group were similar to the whole study group. There are no published 
datasets of similar late assessments in known dengue cases to compare with, except 
one prospective study in Indonesia showing the PRNT titer before and after
67
Chapter 3
symptomatic dengue in 11 children (10 days - -lyear) [175]. When I applied our rule 
to their PRNT data, immune status was correctly assigned in all 11 patients [175]. In 
summary, while I would recommend assessing the all-inclusive models against a new 
gold standard to define immune status (potentially a new PRNT assay using currently 
circulating virus strains) I believe that the current data are acceptable for my analyses.
The only other flavivirus known to circulate locally is JEV. Previously the virus was 
endemic in southern Vietnam but over the last 10 to 15 years the number of 
symptomatic cases seen at HTD has decreased markedly, likely reflecting societal and 
environmental changes, and possibly the effects of vaccination as well. Vaccination 
against JEV is now available in Ho Chi Minh City, but as it is not part of the 
Expanded Program of Immunization it is not free and there is little information on 
uptake. Although no study participant had a history of encephalitis it is possible that 
some participants had experienced asymptomatic or pauci-symptomatic JEV infection 
in the past, or that some participants may have received JEV vaccine. However as the 
PRNT panel did not include measurement of anti-JEV antibodies the contribution of 
cross-reactivity to this virus remains unknown. Algorithms developed on the basis of 
these data should be applicable for use in environments with similar JEV exposure, 
but may not be relevant where the JEV epidemiology and/or vaccine exposure is 
different. This may be particularly important with respect to the indirect IgG assays, 
and there is evidence from sero-surveillance studies on travelers that vaccination with 
JEV or YF prior to travel can lead to false positive results on dengue indirect IgG tests 
[120,176]. However it has been suggested that use of a different cutoff could improve 
differentiation in these circumstances [177]. Despite this, in our context the all- 
inclusive model based on the Panbio Indirect IgG performed well against the gold 
standard PRNT at 6  months suggesting that cross-reactivity with JEV was not a major 
issue.
In summary, in this chapter I have presented my work to develop diagnostic 
algorithms aimed at differentiating primary from secondary dengue during the acute 
illness phase. The variety of systems currently in use by different groups around the 
world reflects the general feeling that none of them are entirely satisfactory, and
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highlights the need for a more effective algorithm. Of course no diagnostic method 
can ever be 1 0 0 % sensitive and specific, particularly when the gold standard has 
limitations, but it is important to understand the confines within which any test has 
acceptable accuracy. By describing the acute serological responses in fine detail in 
this large group of confirmed dengue patients this work has contributed to our overall 
knowledge of the typical patterns seen, and is helpful in defining the general 
limitations associated with attempting to define immune status during the acute 
illness. For our use in Vietnam the daily cutoffs I have derived from the all-inclusive 
models based on the in-house capture IgG and the capture IgM/IgG ratio should prove 
useful and cost-effective, particularly after day 4-5 of illness. However given the 
difficulties of generalizing in-house assays in the wider context, the all-inclusive 
model based on the commercial Panbio Indirect IgG kit is more suitable for defining 
immune status for general pathogenesis research, especially in the early phase before 
day 4-5 of illness. Ideally I would have liked also to assess the accuracy of 
commercial capture ELISAs in the late acute phase, but financial constraints 
precluded daily testing of all the specimens with such kits to define day specific 
cutoffs. Given that the participants in the studies described here were mainly children 
and young adults, reflecting the epidemiology of symptomatic dengue in southern 
Vietnam, ideally the generalizability of the Panbio Indirect IgG algorithm should be 
tested in other populations with different endemicity and a wider age range, and if so 
it might be possible to pursue a targeted assessment of commercial IgG and IgM 
assays focused on the late acute phase.
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Chapter 4
PLASMA VIREMIA KINETICS IN DENGUE; THE INFLUENCE 
OF SEROTYPE AND IMMUNE STATUS, AND ASSOCIATIONS 
WITH CLINICAL OUTCOMES
4.1 Introduction
In addition to immune status, plasma viremia is considered to be one of the crucial 
factors contributing to dengue pathogenesis and the overall severity of disease. It is 
also commonly used as an endpoint in clinical trials of dengue therapeutics [36, 130]. 
However, as yet the magnitude and kinetics of plasma viremia are poorly understood, 
especially with respect to differences by serotype, or to relationships with immune 
status. Although there have been several studies examining these relationships in 
dengue patients in the past, the results have been rather inconsistent, at least in part 
due to insufficient overall case numbers being enrolled to allow differences between 
subgroups of patients to be reliably assessed [37 , 38-45]. In addition little attention 
has been paid to the time point in the evolution of the disease when the measurements 
were obtained -  yet it is clear that plasma viremia differs markedly between and 
within subjects according to the day of illness. Finally, although there are limited data 
available for DENV1 and DENV2, in general reporting higher viremia in DENV1 
than in DENV2, there is very little information published for the other serotypes.
For a number of years our group has been carrying out studies to characterize the 
clinical phenotype of dengue, recruiting patients from the early stage of fever and 
following them daily throughout the evolution of their illness, whether managed as 
outpatients or hospitalized because of worsening clinical status. As well as clinical 
data, in most case we have serial daily samples available for examination of viral and 
immunological characteristics. Therefore I planned to use these samples to obtain a 
detailed picture of the magnitude and kinetics of plasma viremia during the acute 
phase for the three main serotypes DENV1, DENV2, and DENV3, circulating in
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Vietnam between 2006 and 2008, and to correlate these findings with data on the 
clinical phenotype of the patients. Unfortunately DENV4 has been rather uncommon 
in Vietnam in recent years, and has only been identified as a significant contributor to 
the local disease epidemiology since 2012, so I was not able to include assessment of 
this serotype in my study.
To properly understand these relationships, an accurate assessment of immune status 
is necessary, and in our previous experience the methods available have been 
unreliable. In Chapter 3 I described a number of models that I developed to 
differentiate primary from secondary dengue, derived from analysis of daily acute 
serological responses in 249 well-characterized dengue patients for whom immune 
status was assigned on the basis of PRNT results obtained 6  months after the illness 
episode. Although the model based on the Panbio Indirect IgG demonstrated the best 
performance with respect to this independent gold standard, this test was not included 
in the diagnostic work-up of the patient groups available to me for this study. In- 
house IgM and IgG capture ELISAs are routinely performed for all participants in our 
dengue research studies at OUCRU. As reported in Chapter 3 I found that the 
performance of the in-house capture IgG alone, and the in-house capture IgM/IgG 
ratio was comparable, with an overall accuracy of 0.84 for both models. However, 
when each illness day was considered separately the performance of the model based 
on the capture IgM/IgG ratio was more stable, as the accuracy of the in-house capture 
IgG model was rather reduced in the early acute phase (accuracy 0.76 on Day2). 
Therefore I decided to use the all-inclusive model based on the in-house capture 
IgM/IgG ratio to distinguish primary from secondary dengue for the study of viremia 
kinetics described here.
4.2 Purpose of the study
The aim of this study was to investigate the kinetics of plasma viremia for the dengue
serotypes (DENV1, 2, 3) circulating in southern Vietnam between 2006 and 2008, in
regards to immune status and association with clinical parameters, using a stored
sample bank from over 950 acute dengue cases followed during that time period.
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4.3 Materials and methods
4.3.1 Patients and samples
The data and samples used for this study originated from two prospective descriptive 
studies of dengue in children, aged 5 - 1 5  years, which took place in Ho Chi Minh 
City, Vietnam, between 2006 and 2008: one focused on out-patients while the second 
study recruited hospitalized patients. These studies have been described elsewhere 
and were approved by both the Ethical committee of HTD and the Oxford Tropical 
Research Ethics Committee [44]. Briefly, children with suspected dengue seen at one 
of three clinic study sites across the city, or admitted to the HTD, within 72h of fever 
onset were eligible for enrolment providing a parent or guardian gave written 
informed consent and children over 12 years gave assent. Out-patients were seen daily 
by study staff until afebrile for two consecutive days while hospitalized patients was 
monitored daily until discharge. Detailed clinical information was recorded in a 
standard format and a 1ml EDTA blood sample was obtained for clinical tests 
(haematocrit estimation and platelet count), RT-PCR and serological diagnosis. Clinic 
physicians were responsible for all management decisions independently of the study 
protocol; if hospitalization was considered necessary the children were admitted to 
HTD and the daily assessments continued. All patients were invited to attend for 
review 2-4 weeks from illness onset.
Definitions used in this study are as follows: the day of reported fever onset was 
defined as day of illness 1 (Dayl). The platelet nadir was the lowest platelet count 
measured between days 3-8 of illness. The percentage haemoconcentration was the 
percentage increase in haematocrit comparing the maximum value recorded between 
days 3-8 of illness, to a baseline value taken as the lowest value obtained on or before 
illness day 2 or after day 14, provided the platelet count on the same sample was 
more than or equal to 200,000 cells/pl. If there was no appropriate baseline value for 
an individual patient we used the local population mean, matched for age and sex, and 
taken from a local database of more than 1000 healthy Vietnamese subjects. Shock 
and other severe complications were defined according to the WHO 2009 guidelines 
[1 ].
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4.3.2 Laboratory assays
The laboratory methods used for the daily acute illness specimens are described in 
Chapter 2 (Materials and Methods), including methods for the two-step realtime RT- 
PCR and the IgM and IgG capture ELISAs.
The two-step realtime RT-PCR has been demonstrated to be equally sensitive for 
DENV1, 2, and 3, i.e. detection of similar amounts of the standard for each serotype is 
equivalent [44]. Serial plasma samples from each patient were assayed on the same 
day and grouped by serotype, and all assays were done blind to the clinical outcome.
4.3.3 Distinguishing primary from secondary dengue viral infections
The all-inclusive model based on the in-house capture IgM/IgG ratio developed in 
Chapter 3 was used for defining immune status. A case was defined as primary if the 
in-house capture IgM/IgG ratio was equal to or exceeded the cutoff for that day, and 
as secondary if the ratio was below the cutoff for that day (Table 4-1). Usually, each 
patient had two samples for serology tests: one obtained at enrolment (within 72h of 
fever onset) and one at defervescence (outpatients) or discharge (hospitalized cases). 
For those cases with only one sample available for defining immune status (second 
sample missing or day of illness at sampling was out of the range of Day2 - Day7), 
immune status was defined based on this single sample. In cases where there were 
two samples available, both within the defined range of Day2-Day7, the later sample 
was used to define immune status given the slightly better performance of the model 
in the later phase of the acute illness compared to the early phase.
Table 4-1: Cutoffs based on the in-house capture IgM/IgG ratio for 
differentiating primary from secondary dengue
Day of illness
2 3 4 5 6 7
In-house capture IgM/IgG ratio 1 . 8 1 . 6 1.4 1.3 1 .1 1 . 0
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4.3.4 Statistical analysis
Demographic information (age, sex, day of illness, days of sequential follow-up, 
hospitalization), laboratory parameters assessed at enrolment (platelet count (PLT), 
enrolment haematocrit (HCT)), and clinical outcomes (platelet nadir, percentage 
haemoconcentration, occurrence and severity of bleeding, and shock) are described by 
serotype and immune status. The continuous variables are summarized as median 
(IQR) while the categorical variables are summarized as frequency and percentage.
For viremia, the value obtained on day of illness 3 (Day3_viremia), the proportion of 
participants remaining viremic on day of illness 6  (Day6 _viremia), the area under the 
curve for the serial viremia measurements obtained between days 3-6 of illness (AUC 
Day3_6), the highest observed value of viremia (max_viremia), the day of illness at 
the max_viremia, and the time of viral clearance were summarized. The time of viral 
clearance was defined as the day of illness on which the RT-PCR first became 
negative and remained negative. In all cases viremia was log 10 transformed before 
doing the analysis. All the comparisons were predefined. Viremia parameters were 
compared by immune status (primary vs. secondary infections) within serotypes (3 
comparisons) and by serotype (DENV1 vs. DENV2 vs. DENV3) within immune 
status ( 6  comparisons, 3 for primary, and 3 for secondary infections). To account for 
multiplicity due to the 9 pair-wise comparisons, p-values and associated confidence 
95% confidence intervals were adjusted using a single-sep method to protect the 
family-wise error rate. Of note, this achieves the same goal as the familiar Bonferroni 
method (which would imply multiplying the raw p-values by 9) but makes more 
efficient use of the correlation between the different pair-wise comparisons. These 
multiplicity-adjusted comparisons were implemented based on regression models 
which included the group, i.e. the combination of serotype and immune status, as a 
covariate using the companion R package multcomp v 1.3-7 [178].
To assess associations of viremia with clinical outcome measures I chose the Day3 
viremia level, as this was available for almost all participants, and examined 
relationships with outcomes such as the platelet nadir, overall percentage 
haemoconcentration, and progression to shock.
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Linear regression was used for continuous outcomes, logistic regression was used for 
categorical outcomes and Cox regression was used for time to viral clearance. In 
addition, as participants were from 2  different studies, all the analyses were adjusted 
for study. Day of illness at enrolment was adjusted in analyses of max_viremia and 
the day of max_viremia. Interactions between immune status and DENV serotype 
were also investigated for the analyses of associations between viremia level on Day3 
with clinical outcomes. All analyses were performed using R, version 3.1.1 [162].
4.4 Results
4.4.1 Patients’ characteristics
In total, 631 and 321 confirmed dengue patients with fever <72h were enrolled in the 
hospital and community based studies respectively, between 2006 and 2008. In view 
of the low numbers, patients infected with DENV4 were excluded. Similarly, those 
for whom a serotype could not be identified, or where more than one serotype was 
found, and patients for whom the immune status could not be defined given the 
information available, were excluded from the analysis (Figure 4-1). Characteristics 
of patients from each study are summarized in Table 4-2.
Eight (3%) patients from the community study were hospitalized for monitoring. The 
proportion of patients with primary and secondary dengue was quite similar in the 
hospital and community studies (the proportion of secondary cases was 50% and 51% 
respectively). DENV1 predominated in this analysis as well as in southern Vietnam 
during this time period. There were more DENV3 infected patients in the community 
study than in the hospital study (the proportions of DENV1, DENV2, and DENV3 in 
the hospital study were 67%, 19%, 14% and in the community study were 63%, 14% 
and 23% respectively). In both the community and the hospital based patient groups, 
DENV2 infection was more likely to be associated with secondary dengue than the 
other serotypes. Characteristics of all the patients from both studies are summarized 
by immune status and serotype in Table 4-3.
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Chapter 4
Table 4-2: Characteristics of patients from the hospital and community studies
Study Hospital study Communitystudy
Number 571 313
Patients hospitalized NA 8(3)
Serotypes DENV1 384 (67) 197(63)
DENV2 107(19) 45(14)
DENV3 80 (14) 71 (23)
Immune status Primary 287 (50) 154 (49)
Secondary 284 (50) 159 (51)
Demographics
Age (years) 1 2 (10 -13 ) 11 (9 -1 4 )
Sex (Male) 383 (67) 165 (53)
Day of illness at enrolment 1 1 2  (2 ) 55(18)
2 165 (29) 147 (47)
3 394 (69) 111 (35)
Enrolment parameters
Platelet (1,000 cells/pl) 162(121-208)°°
187
(151-230)°°
Haematocrit (%) 39.0(37.2-41.5)°°
38.8
(36.6-41.1)°°
Bleeding at enrolment 113(20) 13(4)
Skin bleeding only 94 (17) 5(1.6)
Mucous membrane bleeding 19(3) 8  (2 .6 )
Clinical outcomes
Days of sequential follow up 5 ( 4 - 6 ) 5 ( 4 - 5 )
Platelet nadir (xl,000 cells/pl) 73.6(45.3-110)
98.0 
(70 .0- 139)
Day of illness at platelet nadir 6 ( 5 - 7 ) 6 ( 5 - 6 )
Percentage haemoconcentration (%) 14.1(8.0-22.5)
11.9
(6.0-19.6)
Development of shock 36(6) 3(1)
New bleeding after enrolment 263 (46) 206 (6 6 )
Skin bleeding only 231 (40) 190 (61)
Mucous membrane bleeding 32 (6 ) 16(5)
The continuous variables were presented as median (IQR) while categorical 
variables were presented as number (%).
There were a) 3, b) 9 missing values.
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There were no major differences in demographic parameters among the groups. There 
were more male (62%) than female patients (38%) in both studies. The median age of 
the patients overall was 12 (IQR 9 - 13) years. Although in the hospital study, age did 
not differ between the primary and secondary dengue cases, in the community study, 
secondary dengue patients were more likely to be older than primary dengue patients 
(median (IQR) = 1 1  ( 8  -  13) and 1 2  (10 -  14) years for primary and secondary 
dengue respectively).
Patients in the hospital study tended to enroll later, with 31% and 65% of patients 
enrolled to the hospital and community studies respectively before Day3, and were 
more likely to remain under observation in the study for longer than patients enrolled 
in the community study (p <0 .0 0 0 1 , linear regression, adjusted for day of illness at 
enrolment). Analyzing the two studies separately showed that a) in the hospital study, 
patients infected with DENV3 compared to other serotypes presented earlier while b) 
in the community study, primary dengue cases presented earlier (p=0.02 and 0.03 
respectively, linear regression, adjusted for immune status or serotype respectively). 
Within each study (hospital versus community) the numbers of days that patients 
were monitored did not differ between serotypes or by immune status.
The platelet counts at enrolment were lower in secondary than primary dengue in 
both studies (median (IQR) = 167,000 (130,000 -  215,000); 156,000 (106,000 -
2 0 2 .0 0 0 ) for primary and secondary dengue in hospital study; and 190,000 (161,000 -
244.000); 183,000 (140,000 -  121,000) for primary and secondary dengue in 
community study respectively), but only reached statistical significance in the 
hospital study (p=0.003 and 0.1 respectively, linear regression, adjusted for serotype 
and day of illness at enrolment). However, the HCT at enrolment was not 
significantly different between the two immune status groups or between the 
serotypes (all p > 0 .1 , linear regression, adjusted for serotype or immune status and 
day of illness at enrolment) in either of the two studies. Considering the whole illness 
course the platelet nadir was generally lower in the hospital than the community study 
participants; when split by immune status the platelet nadir was lower in secondary 
than primary dengue among community participants but not among the hospital study 
participants (p<0 . 0 0 1  and 1 . 0  respectively, linear regression, adjusted for serotype).
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Overall haemoconcentration were not significantly different between the two study 
groups. However, overall haemoconcentration was generally lower in DENV3 
infected patients than in patients infected with other serotypes (p=0.02 and 0.04 for 
hospital and community studies respectively, linear regression, adjusted for immune 
status).
A total of 3 (1%) and 36 (6 %) patients from the community and hospital-based studies 
progressed to dengue shock syndrome, on average 3 days after study enrolment. No 
differences were apparent between the serotypes or immune status groups in the 
development of shock, but the number of events was small. On examination at 
enrolment, patients from the hospital study had more bleeding, including skin and 
mucous bleeding than patients from the community study (20% versus 4% 
respectively). Considering bleeding that developed while under observation, patients 
enrolled in the community study had more skin bleeding documented than patients in 
the hospital study (61% versus 40% respectively), but the rate of mucous membrane 
bleeding (primarily gum bleeding and/or epitasis) were similar. One explanation is 
that patients from the hospital study presented later than patients from community, so 
at enrolment, there were more bleedings observed in patients from hospital study. 
Bleeding at anytime (including enrolment and new bleeding after enrolment) was still 
a little higher in community study than hospital study (66% versus 58% in community 
and hospital studies respectively), but mucous bleeding was higher in hospital study 
(9% versus 5% in hospital and community studies). However no patient in either 
study experienced severe bleeding requiring any intervention. Differences in the rate 
of identification of skin petechiae and bruising between the study populations likely 
reflects the level of attention to detail of the study staff in assessing these features — 
busy hospital-based study staff may be less likely to document what they see as very 
minor abnormalities. There was no difference in development of bleeding 
manifestations between the two immune statuses or among serotypes.
These analyses indicate that the two study populations differed (Table 4-4), with the 
hospital population generally more severely affected than the community population 
at the same time point in their illness evolution -  likely reflecting the decision
(independent of the study) for the subject to be hospitalized.
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Chapter 4
4.4.2 Viremia kinetics
Enrolment viremia was not significantly different between the two study groups 
(median (IQR) = 7.4 (6 . 6  -  8.1) and 7.7 (6 . 8  -  8.4) loglO copies/ml for the hospital 
and community studies respectively, p=0.7, linear regression, adjusted for day at 
enrolment, serotype, immune status). For the main analyses examining relationships 
with viremia I therefore pooled the data from the two study groups, but, recognizing 
the differences discussed above in the characteristics of the participants involved, I 
included an adjustment for the study (hospital versus community) in all comparisons.
A number of parameters describing viremia among the 884 participants involved in 
the pooled analysis are summarized in Table 4-5, including viremia on day of illness 3 
(Day3_viremia), proportion still with measurable viremia on day of illness 6  
(Day6 _viremia), area under the curve for serial viremia measurements between days 
3-6 of illness (AUC Day3_6), the highest observed value of viremia (max_viremia), 
the day of illness when the max_viremia was documented and time of viral clearance . 
Viremia kinetics is also presented in Figure 4-2, individually by serotype and immune 
status.
Comparisons indicate that the viremia kinetics differ significantly according to the 
immune status for both DENV 1 and DENV3, but not for DENV2 infections. 
Specifically, in DENV1 infection, viremia on Day3, area under the viremia curve 
from Day3 to Day6 , and the maximum observed viremia level, were consistently 
higher in primary then secondary dengue. Similar results were seen in DENV3 
infection, except for the max_viremia, the significance was not reached (p=0.1). The 
odds of remaining viremic on Day 6  was also approximately 3 - 4  times greater for 
primary DENVI and DENV3 infections compared to secondary infections with the 
same serotype (OR (95% Cl = 0.30 (0.18 -  0.53) and 0.27 (0.08 -  0.90) for secondary 
compared to primary DENV1 and DEND3, respectively). This comparison suggests 
that viremia generally lasted longer in primary than secondary DENV1 and DENV3 
infections (Figure 4-3), which was supported by the analysis for viremia clearance 
times shown in Table 4-6.
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Figure 4-3: Kaplan-Meier plot of plasma viremia. The figure shows a Kaplan- 
Meier plot indicating the proportion of patients remaining positive for dengue virus by 
R T P CR in primary and secondary infections for a) DENV1, b) DENV2 and c) 
DENV3
The day on which the maximum viremia measurement was recorded did not differ 
significantly between the two immune status groups in DENV1 and DENV3 
infections, but in most cases the maximum viremia was actually recorded on the day 
of enrolment to the study. There were no significant differences between primary and 
secondary dengue DENV2 infections for all the parameters assessed (all p values > 
0.8).
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The results support the view that viremia is influenced by the infecting serotype as 
well as the immune status of the subject. So I examined the effect of serotype on 
viremia kinetics by stratifying the analysis by immune status. In primary dengue, 
viremia was generally higher in DENVI infections as compared to DENV2 and 
DENV3, while in secondary dengue the various measures for viremia were generally 
lowest in the DENV3 infections. Specifically, viremia on Day3, the area under the 
viremia curve from Day3-6 and the maximum observed viremia were all greater in 
primary DENV1 than primary DENV2 and DENV3 infections. Primary DENV1 
infections also had longer time to viral clearance than primary DENV2 and DENV3 
infections, though the statistical significance was not reached. However, I found no 
difference in the viremia parameters when comparing primary DENV2 and DENV3 
infections. With respect to secondary dengue, viremia on Day3, area under the 
viremia curve from Day3-6, the maximum observed viremia and the time to viral 
clearance were all higher and/or longer in DENV1 and DENV2 infections than in 
DENV3 infections. There was no significant difference in viremia kinetics between 
secondary DENV1 and DENV2 infections (Table 4-7).
4.4.3 Association of viremia on Day3 and clinical outcomes
I used viremia level on Day3 to assess associations with clinical outcomes, as early 
viremia has the potential to be applied practically in the future if shown to be useful. 
Higher viremia on Day3 was independently associated both with a lower platelet 
nadir, and with greater overall haemoconcentration (both p values <0 .0 0 1 , linear 
regression with platelet nadir or haemoconcentration as outcomes, log 1 0  viremia at 
Day3, immune status, serotype, interaction of immune status and serotype, study, 
value (PLT or HCT) at Day 3 as co-variables). With an increase of 1 log DENV RNA 
copies/ml, the platelet nadir decreased -7,600 (-9,100, -6,100) cell/pl and 
haemoconcentration increased by 1.25% (0.76 -  1.75). In addition, development of 
shock was associated with higher viremia on Day3 (p=0.002, logistic regression with 
shock as the outcome, log 10 of viremia at Day3, immune status, serotype, interaction 
of immune status and serotype, study as co-variables). Thus patients experiencing a 
dengue infection with the same serotype, immune status and hospitalization status
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Chapter 4
who had higher viremia had a greater risk of progressing to shock; with an increase of 1 
log DENV RNA copies/ml the odd of shock increased 1.63 (1.21 -  2.28) times. Higher 
viremia on Day3 was also associated with new bleeding which developed after 
enrolment in general, skin bleeding only and mucous bleeding (all p <0.03, logistic 
regression, adjusted for immune status, serotype and study). Specifically, with an 
increase of 1 log DENV RNA copies/ml the odds for the appearance of bleeding (both 
skin and mucous) increased 1.2 (1.1 -  1.3) times; the odds of skin bleeding increased
1.1 (1.0 -  1.2) times; and the odds of mucous bleeding increased 1.3 (1.0 -  1.7) time.
4.5 Discussion
In this study, I confirmed and expanded the current knowledge base regarding the 
influence of immune status and serotype on the magnitude and kinetics of DENV 
viremia, by carrying out detailed assessments on almost 900 patients infected with 
DENV1, DENV2, and DENV3. I also confirmed associations between the magnitude 
of the viremia response and a number of clinical outcomes (eg platelet nadir and 
percentage haemococentration), and was able to show for the first time an association 
between higher viremia during the early febrile phase and subsequent development of 
DSS. Higher viremia in the early febrile phase was also associated with a slightly 
greater risk of developing bleeding, both from the skin and mucous membranes.
Previous studies have shown inconsistent results when assessing associations between
viremia and immune status, or viremia and dengue severity [37-43]. In addition to
generally small sample sizes, viremia was rarely related to the day of illness at
sampling in these studies. However, in a previous report from our group involving
around 170 patients mainly infected with DENV1 and DENV2, and in a paper
examining secondary DENV3 infections in 54 cases, in both of which timing was
carefully considered, associations between higher viremia in the febrile phase and a
lower platelet nadir and/or greater percentage haemoconcentration during the
subsequent course of the illness, were demonstrated [38, 44]. Another factor that has
made interpretation of these types of data difficult in the past, has been the method used
to classify dengue severity -  several groups have used the WHO 1997 classification,
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where distinction between DF and DHF is not always clear. This study has the 
advantage of a much larger sample size than all previous studies, allowing subgroup 
analysis by serotype and immune status to be performed, as well as rigorous clinical 
sampling protocols with daily samples obtained from almost all patients during the 
acute illness. Finally the decision to assess the clinical outcomes separately, with strict 
definitions used for each parameter, reduces the likelihood of blurred demarcation lines 
between severity groups.
It is interesting to see that similar patterns, albeit with differing magnitude of responses, 
were observed for DENV1 and DENV3, but that the pattern of viremia kinetics for 
DENV2 was rather different. Although DENV1 infections resulted in higher viremia 
than DENV3 infections generally, the influence of immune status was consistent, with 
primary infections of the appropriate serotype typically resulting in higher viremia than 
secondary infections, during the time window when measurements were possible. 
However the responses observed during DENV2 infections were different; although 
primary DENY1 infections still demonstrated higher viremia than primary DENV2 
infections, this difference was no longer apparent in secondary infections since the 
viremia level in secondary DENV2 infections remained at a level equivalent to that 
seen in primary DENV2 infections -  i.e. viremia was NOT lower in secondary DENV2 
infections. Similarly, although viremia levels were similar between DENV2 and 
DENV3 primary infections, in secondary infections the DENV2 viremia level was 
unchanged while the DENV3 viremia was lower, thus making secondary DENV2 
viremia higher than secondary DENV3 viremia. Regrettably, so few DENV4 infections 
occurred during the study period that I was unable to assess relationships to viremia, 
immune status, or clinical outcomes, for this serotype.
Although these effects of immune status and serotype on viremia kinetics are clear for 
DENV1, DENV2 and DENV3, the results should be interpreted with caution. In this 
study, we tried to enroll patients as early as possible in the febrile phase of dengue, and 
the majority of the patients were actually enrolled on Day 2 or Day 3 of illness. 
However, only a small number of patients were enrolled on Day 1 of illness (reflecting 
the health seeking behavior of the local community), at which point high viremia were
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already detectable in many cases (Figure 4-2). It is only possible to draw conclusions 
from the first viremia time-point forward, when in fact the viremia was already 
declining in most cases. What may have happened in the pre-symptomatic or early 
symptomatic phase of the illness remains a matter of conjecture; thus viremia may peak 
before fever onset, or the time from being infected by a mosquito to developing peak 
viremia may differ by serotype or according to immune status. Unfortunately it is rarely 
practical to enroll dengue patients earlier in their disease course, in particular in the pre- 
symptomatic phase, in sufficient numbers to address these questions adequately. One 
potential area of interest to examine these questions in more detail is human challenge 
studies. Currently, because of ethical concerns about the potential to increase the risk 
for severe disease, human challenge studies are conducted in very limited 
circumstances, generally relating to vaccine development research and usually 
involving attenuated viruses in naive populations. In the past however, challenge 
studies using naturally occurring viruses were performed, most notably in the 
Philippines in the 1920s and by Albert Sabin’s group in the 1940s and 50s. In a recent 
review of Sabin’s human challenge experiments, evidence was presented that the 
incubation period for secondary dengue was shorter than for primary dengue (median 
incubation time of 4.2 and 6.5 days for secondary and primary infections respectively) 
[179]. In these experiments, it was not possible to measure viremia but one could 
hypothesize that in the very early phase of a secondary dengue infection, viremia levels 
are enhanced by ADE resulting in a rapid rise to peak viremia, potentially earlier than 
in a primary infection; at the same time the rising viremia triggers an earlier immune 
response, so that by the time patients present to clinical care the combination of a high 
early peak viremia in the presymptomatic phase, together with an earlier more 
aggressive immune response, result in apparently lower plasma viremia levels in 
secondary cases. The situation with DENV2 appears to be different, but at present it is 
difficult to propose a theory to explain why this should be.
Another limitation to consider is that the viremia measurements in this study were done 
on plasma using realtime RT-PCR. Dengue virus has been found in other tissues, and 
the true contribution of different viral reservoirs (eg. splenic lymphoid tissue, 
haemopoetic cells) to dengue pathogenesis remains uncertain [12, 14-16, 180]. In
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addition, realtime RT-PCR measures total plasma viremia but cannot differentiate 
between infectious and non-infectious viral particles. Although there is a reasonable 
correlation between the amount of RNA measured by PCR and quantization of 
infectious virus by plaque assay techniques, how this correlation is affected by immune 
status or serotype is unknown [131, 181]. In one study measuring NS1 levels, evidence 
was presented that NS1 in immune complexes could evade detection in ELISA based 
assays [182]. Anti-dengue IgG levels were significantly higher in the secondary dengue 
cases, potentially explaining the lower viremia levels detected in secondary than 
primary DENV1 and DENV3 infections. However, in the RNA extraction step before 
performing the PCR, the plasma is processed with strong lytic reagents and at high 
temperatures, both processes that are likely to separate immune complexes, so I think 
that the contribution of immune complex formation to the findings observed in this 
work is likely to be small.
Another limitation to consider is that fact that the participants were from two different 
studies, one hospital based and one community based. Although the study objectives, 
study procedures and execution were very similar, inevitably the enrolled patient 
populations differed slightly, with the hospital population generally being more 
severely affected than their community counterparts. However, we recognized this 
difference and were careful to include an adjustment for the study type in all relevant 
analyses. Another point to stress is that relatively few true severe dengue cases were 
included, even though the overall study population numbered almost 900 confirmed 
dengue cases. Estimates vary of the proportion of dengue infections that progress to 
severe disease, but in our context the figure is thought to be around 3-5% of 
symptomatic cases who go on to develop DSS. However, in practice many patients do 
not present to facilities with the capacity to enroll into research studies until late in the 
disease evolution; we assume that by following a large group of symptomatic patients 
from the early febrile phase we will capture a representative sample of the clinical 
spectrum of patients who do subsequently progress to severe dengue, but without a 
formal cohort design where all subjects from a given area or population are followed 
actively over a period of some years it is not possible to be certain that the
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characteristics of those who develop severe disease are not in some way different to 
those whom we capture at an early stage of their illness using our current study design.
However, despite these caveats this represents the largest study of its kind to date. In 
conclusion, I found that the magnitude and kinetics of dengue plasma viremia was 
influenced by both the immune status of the patient and by the serotype of the current 
infection. Although what happened before fever onset remains unknown, it is also also 
clear that viremia in the early febrile phase (Day 3) was associated with several 
important markers of more severe dengue disease: a lower platelet nadir, higher overall 
haemoconcentration, and a greater risk for development of shock and bleeding. As 
quantitative PCR becomes more widely used in clinical practice in the management of 
other infectious diseases (such as HCV and HBV) the utility of measuring dengue 
plasma viremia as a potential progostic marker might be considered. Further studies 
which include viremia as a predictor will need to be conducted to examine this 
hypothesis in detail, but in endemic areas where healthcare facilities are currently 
overburdened by large numbers of patients hospitalized for monitoring, then additional 
prognostic markers, if shown to be robust, would be welcomed.
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Chapters
EFFECT OF EARLY PREDNISOLONE THERAPY ON DENGUE 
VIREMIA, NON-STRUCTURAL PROTEIN 1 (NS1) KINETICS AND 
A RANGE OF IMMUNOLOGICAL CORRELATES IN DENGUE
5.1 Introduction
A small number of anti-viral agents have been trialed to examine their effects for 
dengue treatment [130, 135, 136]. Although these agents had no significant adverse 
effects in the trials, they were also not successful in reducing plasma viremia or 
preventing the development of complications. An alternative strategy aimed at 
improving outcome is to use immune modulation, such as corticosteroid therapy. 
Corticosteroids have been used widely to treat diseases where the host immune 
response is thought to make a significant contribution to pathogenesis. Evidence of 
benefit has been shown in infectious diseases such as TB meningitis, bacterial 
meningitis, leprosy and recently, community acquired pneumonia [183-186]. 
Corticosteroids have been shown to inhibit transcription of pro-inflammatory genes and 
induce transcription of anti-inflammatory genes [187], and have been demonstrated to 
suppress both T cell and cytokine responses, which are both hypothesized to contribute 
to the endothelial dysfunction/vasculopathy that can occur in dengue [188, 189].
In the previous chapter, I described how viremia kinetics differed by serotype and 
immune status. In this chapter, I will present my work to investigate viremia kinetics in 
dengue under the effect of an immune modulator belonging to the corticosteroid family, 
in this case prednisolone. Recently a randomized controlled trial of early oral 
prednisolone therapy was performed in 225 confirmed dengue cases in Vietnam. 
Although the trial was primarily designed to assess safety, we did not detect any 
reduction in the severity of plasma leakage or other recognized complications of 
dengue [36]. My work looked at the question of whether, by suppressing the immune 
response in dengue, prednisolone therapy might prolong the plasma viremia and
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antigenemia of NS1. In addition, I looked at a variety of factors involved in the immune 
response, to investigate the effect of prednisolone thereapy at both protein and 
transcriptional levels in order to try to better understand dengue immunopathogenesis.
5.2 Materials and Methods
Laboratory methods including IgG and IgM capture ELISA, one-step multiplex 
realtime RT-PCR, qualitative NS1 assays, T cell phenotyping, cytokine quantification, 
microarray and RT-PCR for validation were performed as described in Chapter 2 
(Materials and Methods).
5.2.1 Study population
A randomized placebo-controlled trial assessing the safety of early oral corticosteroid 
therapy in dengue patients was conducted at the Hospital for Tropical Diseases in Ho 
Chi Minh City, Vietnam, between August 2009 and January 2011 [36]. Ethical 
approval was obtained from the Ethical Committee of the Ministry of Health of 
Vietnam and the Oxford Tropical Research Ethics Committee. The trial was registered 
with the ISRCTN Register (ISRCTN39575233). Once written consent was obtained, 
225 patients aged from 6-20 years old with fever for less than 72h and a positive NS1 
rapid test (Dengue Duo Rapid Test, SD, Korea) were randomly allocated to oral 
treatment with either high-dose prednisolone (2mg/kg), low-dose prednisolone 
(0.5mg/kg), or identical placebo for 3 days (75 patients in each arm). The research 
blood specimens that are the basis of the results described in this chapter were collected 
as part of the trial protocol at pre-specified time-points: daily samples from enrolment 
to discharge were used for viremia quantification and NS1 ELISA assays; samples at 
enrolment (pre-treatment), 2 days post-treatment initiation, and at follow up (a median 
of 29 (IQR 27 - 30) days after enrolment) were collected for analysis of plasma 
cytokines and gene expression microarray; samples at enrolment and discharge (4-11 
days post-treatment) were assayed with in-house IgM and IgG capture ELISAs. In 
addition, samples at discharge were used for analysis of T-cell surface phenotype, and 
samples 6 months after illness onset were used for PRNT60 determinations.
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5.2.2 Defining immune status
Because this work was completed before developing the algorithms to differentiate 
primary and secondary dengue infections that I describe in Chapter 3 ,1 used a system 
previously developed at our Unit to define immune status, as described elsewhere [36]. 
In brief, a patient with negative anti-E protein IgG indirect ELISA on the enrolment 
sample (within 72h of fever onset) and no rise in dengue-reactive IgG (in-house capture 
IgG) by day 7 of illness was defined as having a primary infection; in contrast, a patient 
with a positive or equivocal result for the anti-E protein IgG indirect ELISA on the 
enrolment sample and a rise in dengue-reactive IgG greater than that of the IgM by day 
7 of illness, was defined as having a secondary dengue infection.
5.2.3 Microarray data analysis
The raw expression intensity data was extracted from the arrays using GenomeStudio 
software (Illumina). The raw data was normalized to the background by subtracting the 
background signal. This software was also used for data quality control (QC). After 
removing noise by using GenomeStudio, the data was transferred to GeneSpring 
software (Agilent Technologies) for another standard normalization procedure for one 
color array data. In brief, the measurements with intensity values of less than 5.0 were 
corrected to 5.0. Per chip all the signals were normalized to the 80th percentile by 
dividing each value by the 80th percentile value; per-gene normalization accounted for 
variability between probe sets for different genes. Only genes that were confidently 
detected in at least 60% of samples in one of the three treatment groups were used.
The ANOVA t-test developed in GeneSpring Software was used for all comparisons of 
microarray data. Multiple test correction was done using the Benjamini-Hochberg 
method. A fold change of 1.5 was defined as the cut-off for screening significant 
entities. Ingenuity Pathway Analysis software (Ingenuity System, USA) was used to 
explore the networks, the gene ontology, and the canonical molecular pathways related 
to the genes identified. A heatmap of hierarchical clustering was drawn with Multi 
Experiment Viewer software (TM4 Microarray Website Suite). The GEO accession 
number for the microarray data is GSE40165.
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5.2.4 Statistical analysis
The primary comparison between the 3 groups was a linear trend test: a single 
treatment covariate was included with placebo coded as 0, low-dose as 1, and high-dose 
as 2. This was based on linear regression for continuous endpoints, logistic regression 
for binary endpoints and Cox regression for time-to-event endpoints. Comparisons for 
continuous laboratory parameters were adjusted for day of illness at enrolment and the 
enrolment value of the parameter.
For virological factors the following parameters were compared: the area under the . 
curve (AUC) for log-transformed serial measurements of plasma viremia obtained 
between Day3-6 of illness; the number of days from enrolment until the RT-PCR first 
became negative; and the number of days from enrolment to negative NS1 status. In 
addition to day of illness at enrolment and the enrolment values, comparisons of 
viremia and NS1 were also adjusted for serotype and immune status.
For the microarray data I used multivariable linear regression modeling for all 
comparisons of validated PCR results, expressed as delta Ct values, across and between 
the treatment arms. In view of the likely evolution of gene expression during the illness 
episode and the known associations of many of the genes of interest to immune 
parameters, I adjusted for the absolute neutrophil and lymphocyte counts as well as day 
of illness at enrolment and the enrolment value. P values for testing of multiple PCR 
results were corrected using the Benjamini-Hochberg method. The relative expression 
ratio (R) of the genes between the treatment arms was estimated using the delta delta Ct 
formula: R = 2'AACt, with the 95% confidence intervals of R estimated based on the 
basic bootstrap interval method. Genes with significantly different relative expression 
ratios across or between treatment arms (i.e. adjusted p<0.05 and 95%CI not including 
1) were considered up or down regulated as appropriate.
Log transformed values were used for comparisons of cytokine concentrations. IgM 
and IgG levels and T cell phenotypes at discharge, as well as PRNT60 values 6 months 
after illness onset, were compared between the treatment groups using the Mann- 
Whitney test. All the analyses were corrected for multiple testing using the Benjamini- 
Hochberg method.
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All analyses other than those pertaining to the microarray data were performed using R 
- version R2.13.2 [162].
Table 5-1: Baseline characteristics according to treatment allocation
Placebo
(N=75)
Low-dose
prednisolone
(N=75)
High-dose
prednisolone
(N=75)
All patients 
(N=225)
Age [years] 13(12-15) 12(11 - 14) 12(10-14) 13(11-14)
Gender - Male 56 (75) 54 (72) 51 (6 8 ) 161 (72)
Temperature [°C] 38.8 (38.5 - 39.4)
39.0 
(38.6 - 39.6)
38.9 
(38.5 -39.4)
39.0 
(38.5 - 39.5)
Day o f illness at enrolment:
Day 1 0 (0 ) 1 ( 1) 1 ( 1) 2 ( 1)
Day 2 28 (37) 23(31) 29 (39) 80 (34)
Day 3 47 (63) 51(68) 45 (60) 143 (64)
Serotype:
DENV1 41 (55) 46(61) 49(65) 136(60)
DENV2 29(39) 17(23) 11(15) 57 (25)
DENV3 4(5) 9(12) 10(13) 23 (10)
DENV4 1 (1) 2(3) 4(5) 7(3)
Serotype unknown 0 (0 ) 1 ( 1) 1 (!) 2 ( 1)
Immune status:
Primary 22 (29) 2 1  (28) 25 (33) 68(30)
Secondary 43 (57) 39 (52) 35 (47) 117(52)
Unknown 10(13) 15 (2 0 ) 15 (20) 40(18)
Plasma viremia 
[loglOcopies/mL]
N=75 
8.81 
(7.98 - 9.23)
N=74 
8.77 
(8.23 - 9.47)
N=74 
8.96 
(8.08 - 9.57)
N=223 
8.81 
(8.05 - 9.39)
Haematocrit [%] 40 (39 - 43) 39 (37-41) 39 (37 - 42) 39 (3 8 -4 2 )
Platelet count 143 140 143 142
[10A9/L] (108- 172) (1 0 0 - 186) (113-201) (107- 188)
WBC [10A6 dL] 3.8 (2.7 - 5.0) 3.7 (3.0 - 5.4) 4.2 (3.0 - 5.2) 3.7 (2.9 - 5.2)
Neutrophils [%] 67 (59 - 75) 6 8  (58 - 75) 70 (59 - 79) 69 (59 - 76)
Lymphocytes [%] 18(13-26) 19 (13 - 26) 17(11-29) 18(12-27)
All data are presented as number (%) for categorical variables and median (IQR) for  
continuous variables.
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5.3 Results
5.3.1 Patient characteristics
Between August 2009 and January 2011, 225 participants were enrolled in the study 
and randomized to one of the three treatment arms. Baseline characteristics were 
similar in the three treatment groups, Table 5-1. In addition, clinical complications such 
as dengue shock syndrome (DSS), thrombocytopenia, severe bleeding and 
coagulopathy occurred at similar rates in the different treatment arms, and at a rate 
consistent with what is expected in our population. There was no difference in adverse 
events across the 3 groups, except that a higher incidence of hyperglycemia was noted 
with high-dose prednisolone therapy (p=0.07) [36].
5.3.2 Viremia kinetics
There was no difference in viremia kinetics between the three treatment groups (Figure 
5-1), including both the AUC of log viremia from Day3-6, and the time of viremia 
clearance (p=0.8 and 0.9 respectively, multiple linear regression adjusted for day of 
illness at enrolment, pre-treatment value of viremia, immune status and serotype) 
(Table 5-2).
Placebo Low dose prednisolone High dose prednisolone All patients
i i i I i i i t i I I t i i i i t i i t i i i i i i i t
2 3 4 5 6 7 8 2 3 4 5 6 7 8 2 3 4 5 6 7 8 2 3 4  5 6 7 8
Day of illness
Figure 5-1: Dengue viremia kinetics for all serotypes by day of illness. The figure
shows dengue viremia kinetics for all serotypes by day of illness in the three treatment
arms separately and finally with all data combined. The gray lines represent individual
patient data while the colored lines correspond to loess scatter plot smoothers.
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Table 5-2: Effect of early prednisolone on dengue viremia
Placebo Low-doseprednisolone
High-dose
prednisolone P value
AUC 20.96 (16.97 -23.25)
21.29 
(18.85 -23.79)
21.56
(17.99-24.18) 0.8
Days from study 
enrolment to 
viremia 
clearance*
7 (5 - 8) 7 (5 - NE) 8 (5 - 8) 0.9
AUC: Area under curve o f  log viremia from day 3 to day 6 o f illness.
*  The values are expressed as median and inter quartile range. NE: not estimable
5.3.3 NS1 kinetics
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Figure 5-2: Kaplan-Meier plot of NS1. The figure shows a Kaplan-Meier plot 
indicating the proportion of patients remaining positive for NS1 in the three treatment 
groups on each day following study enrolment.
NS1 persisted for a long time in the dengue patients, and many patients in fact 
remained positive at discharge (Figure 5-2). The median (IQR) of days from enrolment 
to negative NS1 status was 5 (3 - 8) days for patients receiving placebo, 5 (3 - 11) days 
for those receiving high-dose prednisolone, and 5 (3 -  not estimable) days for those on
  Placebo
  Low dose - Steroids
  High dose - Steroids
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low-dose prednisolone. There was a borderline trend between patients receiving 
prednisolone and prolongation of NS1 antigenaemia (p=0.08, multiple linear regression 
adjusted for day of illness at enrolment, immune status and serotype).
5.3.4 Differentially abundant gene expression linked to high-dose prednisolone 
therapy
Figure 5-3: Unsupervised hierarchical clustering of the 81 differentially abundant 
elements distinguishing patients that received high-dose prednisolone from 
placebo treated patients 2 days after starting therapy. Individual patient samples (2 
days after starting treatment) are shown in vertical columns while the 81 differentially 
abundant transcripts (from 67 genes) are shown in horizontal rows.
Microarray analysis was carried out in the first 123 consecutive patients enrolled in this 
study. At baseline there were no transcripts identified in the microarray that were
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differentially abundant between the treatment arms. Similarly, there were no 
differentially abundant transcripts between treatment groups in late-convalescence (a 
median of 29 (IQR 27 - 30) days after enrolment) or between placebo and low-dose 
prednisolone patients 2 days after commencing treatment. In contrast, 81 differentially 
abundant transcripts (25 from 21 genes more abundant, and 56 from 46 genes less 
abundant) were detected when comparing whole-blood gene expression profiles 
between high-dose prednisolone and placebo-treated patients 2  days post-commencing 
treatment (median time 43hrs (IQR 42 - 43) for high-dose prednisolone and 43hrs (IQR 
42 - 44) for placebo). In these samples the median time since the last dose of study 
medication was 23hrs (IQR 2 2  - 24) for high-dose prednisolone and 23hrs (IQR 2 2  - 
23) for placebo. Unsupervised hierarchical clustering of the 81 elements that represent 
the high-dose prednisolone-associated signature is shown in Figure 5-3.
5.3.5 Validation by quantitative RT-PCR (qRT-PCR) of the high-dose 
prednisolone-associated gene signature
RT-PCR measurements were performed for 31 (46%) of the 67 genes (81 transcripts) 
on the basis of their having plausible roles in immune function. RT-PCR was 
performed on 600 whole blood RNA samples collected at baseline, 2 days after starting 
treatment, and at the follow-up visit from 223 (99%) of the 225 patients who were 
enrolled into the study.
RT-PCR measurements were highly concordant with the microarray findings in 
demonstrating differences in transcript abundance between high-dose prednisolone 
recipients and patients receiving placebo (Figure 5-4).
We extended these analyses by investigating a dose-response relationship in the 
prednisolone-associated gene expression signature. After adjustment for a priori 
defined baseline variables (day of illness at enrolment, absolute neutrophil and 
lymphocyte count, baseline transcript abundance) a highly significant dose-related 
affect on gene transcript abundance was observed for 31/31 transcripts using trend test 
(Table 5-3). These results collectively define a gene expression signature that is 
associated with high-dose prednisolone therapy in dengue patients.
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Figure 5-4: Fold difference in transcript abundance between high-dose
prednisolone and placebo treated patients 2 days post-treatment. Shown is the ratio 
in abundance of transcripts measured by microarray and by RT-PCR from the 67 genes 
that distinguished high-dose prednisolone treated patients from placebo treated patients. 
Where results from multiple probes in the microarray were available for a single gene 
the mean result was used. Genes have been grouped and annotated according to their 
recognized biological functions.
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Table 5-3: Genes with transcript abundance that were significantly different 
between patients treated with high-dose prednisolone and placebo
No
Gene
Symbol
Microarray RT-PCR
Abundance Fold
change
Relative 
expression 
ratio 
(95% Cl) 
High-dose vs 
Placebo
Relative 
expression 
ratio 
(95% Cl) 
Low-dose vs 
Placebo
Trend test 
P value3
1 ORM1 Higher 1 .8 2.7 (1.5-3.5) NS 1.20E-06
2 ANXA3 Higher 2 . 2 2.5 (1.7-3.1) 4* 0 1 00 5.01E-08
3 IL1R2 Higher 1.9 2.5 (1.5-3.1) 1.7 (1.0-2.1) 1.40E-07
4 CD 163 Higher 2 . 0 2.3 (1.7-2.8) 1.5 (1.1 -1.8) 2.77E-08
5 SLPI Higher 1 .6 2 . 0  (1 .3 -2 .6 ) NS 1.04E-04
6 S100A12 Higher 1.7 1 .8  ( 1 .1  - 2 .2 ) NS 6.54E-06
7 MS4A1 Higher 1.5 1 .6  ( 1 .2 - 1 .8 ) 1.2 (1.0-1.4) 1.31E-05
8 C19orf59 Higher 1 .6 1.6 (1.1-1.9) NS 9.64E-04
9 VNN2 Higher 1 .6 1.4 (1.1-1.7) NS. 2.78E-02
1 0 KIR3DL1 Lower 1.7 1.7 (1.4-2.6) 1.4 (1.1 -2.1) 1.01E-03
11 KIR2DL4 Lower 1.7 1 .6  (1 .3 - 2 .2 ) 1.3 (1.1-1.8) 3.88E-05
1 2 LAIR2 Lower 1.7 1.4 (1.2-1.8) 1.3 (1.1 -1.6) 2.46E-03
13 ZBTB16 Lower 1 .6 1.7 (1.4-2.2) 1.5 (1.3-1.9) 6.42E-07
14 SH2D2A Lower 1.5 1 .6  (1 .3 -2 .0 ) 1.4 (1.2 -1.8) 5.09E-04
15 EOMES Lower 1.5 1.4 (1.2-1.9) 1.4 (1.2-1.7) 8.20E-03
16 GZMB Lower 1.5 1.9 (1.5-2.6) 1.5 (1.2-2.0) 1.57E-04
17 GNLY Lower 1.7 1.7 (1.4-2.2) 1.3 (1.1 - 1.7) 3.67E-04
18 GZMH Lower 1.5 1 .6  (1 .3 -2 .2 ) 1.3 (1.1 - 1.8) 9.01E-04
19 PRF1 Lower 1 .6 1 .6  (1 .3 - 2 .2 ) 1.4 (1.2-1.9) 1.17E-03
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2 0 CTSW Lower 1 .6 1.5 (1.2-1.9) ' NS 1.26E-02
2 1 CCR3 Lower 1 .8 1.8 (1.4-2.5) 1.4 (1.2-2.0) 5.63E-08
2 2 CX3CR1 Lower 1 .6 1 .6  (1 .3 -2 .1) 1.3 (1.1-1.7) 1.16E-03
23 S1PR5 Lower 1 .8 1.9 (1.6-2.5) 1.5 (1.2-1.9) 9.89E-06
24 GPR56 Lower 1.7 1 .8  (1 .5 -2 .6 ) 1.4 (1.1-2.0) 4.74E-04
25 SPON2 Lower 1 .8 2.2 (1.9-3.0) 1 .6  (1 .3 -2 .2 ) 2.04E-07
26 DDIT4 Lower 1 .8 1.9 (1.7-2.4) 1.5 (1.3-1.9) 5.67E-09
27 FGFBP2 Lower 1.7 1.9 (1.5-2.7) 1 .6  (1 .3 -2 .2 ) 2.06E-04
28 MMP23B Lower 1 .6 1.7 (1.4-2.4) .1.4 (1.2-1.9) 1.01E-03
29 CLIC3 Higher 1 .8 1 .6  (1 .3 -2 .1 ) 1.3 (1.1 -1.7)- 3.55E-04
30 MATK Lower 1.5 1.4 (1.2-1.8) NS 7.13E-03
31 PLEKHF1 Lower 1 .6 1.4 (1.2-1.8) NS 6.41E-03
a Allp values were corrected with Benjamini-Hochberg method for multiple test correction.
NS denotes genes that were not significantly different in gene expression between the patients 
receiving low-dose prednisolone and placebo and/or the confidence interval o f the relative 
expression ratio (95% Cl) contained 1.
5.3.6 Phenotypic profile of T lymphocytes and response to prednisolone therapy
The phenotype (HLA-DR, CD38 and Ki-67) of T lymphocytes (CD3+4+ and CD3+8 )^ 
in fresh whole-blood samples collected 4-11 days after commencing treatment was 
determined in 100 consecutive patients. The baseline characteristics of these patients 
are described in Table 5-4 The percentage of CD8+Ki67+ T cells was increased in 
patients treated with prednisolone (p=0.02 for low-dose prednisolone and 0.03 for high- 
dose prednisolone versus placebo, Mann-Whitney test, Figure 5-5); The percentage of 
CD8+CD38+ T cells was also significantly elevated in the low-dose prednisolone group 
but not in the high-dose prednisolone group compared to the placebo patients (p=0 .0 1 , 
Mann-Whitney test, Figure 5-5). However, these associations were not significant after 
adjustment for multiple testing using the Benjamini-Hochberg correction.
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Table 5-4: Baseline characteristics of patients included in T cell phenotypic 
analysis
Placebo Low-dose High-dose
(N=38) (N=31) (N=31)
Sex [Male] 29 (76) 2 1  (6 8 ) 24 (77)
Age [years] 15 (13 -17) 14(12-17) 14(12-16)
WBC [10A6 dL] 5.4 (4.2 - 6.9) 5.2 (4.5-6.1) 5(4.1 -5.7)
Lymphocyte [10A6 dL]*
42.9
(37-48.3)
46.5
(41.4-53.4)
43.1 
(38.4 - 49.7)
Day of illness of sample 
(days)
9 ( 8  -10) 8  ( 8  - 9) 8  ( 8  - 9)
Serotype
DENV1 13(34) 18 (58) 18(58)
DENV2 23 (61) 8  (26) 7(23)
DENV3 2(5) 4(13) 5 (16)
DENV4 0 1(3) 1(3)
Immune status**
Primary 6(16) 7(23) 9 (29)
Secondary 25 (6 6 ) 13(42) 12 (39)
Numbers are median (IQR) or N  (%). No significant difference was found between
the groups. *5 missing data. ** 28 missing (7, 11 and 10 patients respectively in 
the three treatment arms).
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Figure 5-5: Frequency of activated CD8 + (A - B - C - D) and CD4+ (E - F - G - H) T 
cells in peripheral blood at discharge. Shown in each panel is the median ± IQR that 
represents the percentage of T cells positive for Ki67 (A, E), HLA-DR (B, F), CD38 (C, 
G) and triple positive for CD38/HLA-DR/Ki67 (D, H). The number of patients evaluated 
is indicated below D and H.
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5.3.7 Plasma cytokines and prednisolone therapy
Concentrations of 11 cytokines and chemokines were measured in 636. serial plasma 
samples from 223 patients at three time-points: at baseline, 2 days after commencing 
treatment, and at follow-up in late convalescence. Follow-up samples were missing 
from 30 patients (placebo - 1 0 ; low-dose prednisolone - 8 ; and high-dose prednisolone - 
12). Although within the detectable range in 98% of samples tested, the 
cytokine/chemokine concentrations (adjusted for pre-treatment values and day of illness 
at enrolment) were neither significantly elevated nor significantly different between the 
treatment groups 2 days after starting therapy (Table 5-5). An unadjusted comparison of 
values gave similar profiles. Since these findings were unexpected, the accuracy of the 
Bio-plex immunoassay was confirmed by repeating the IFN-y measurement on 72 
patients randomly chosen from 223 patients with serial samples, using a conventional 
sandwich ELISA technique (R&D Systems - USA). Near identical results were found 
(See Figure 5-6).
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1000
1
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£
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□  By multiplex biometrix 
immunoassay
■ I  By sandwich ELISA
—i- - - - - - - - - 1- - - - - - - - - 1- - - - - - - - - r~
Pre- Post­
treatment treatment
“ i-------- 1—
Follow up
Figure 5-6: Comparisons of plasma IFN-y levels measured by two methods: 
multiplex biometrix immunoassay and sandwich ELISA. 72 patients with serial 
samples were randomly chosen from 223 patients for IFN-y sandwich ELISA (R&D 
Systems, USA) and compared with multiplex biometrix immunoassay. No significant 
differences were found between the two methods or between the sample time-points.
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Chapter 5
5.3.8 Serological responses and prednisolone therapy
DENV-reactive IgM and IgG levels in early convalescence (days 4-11 post-treatment) 
were not significantly affected by prednisolone therapy (Figure 5-7). In a subset of 
patients (n=75) who returned for a 6-month follow-up visit, PRNT60 titers to DENV1- 
4 were determined with plasma collected at that visit. No difference was observed 
between treatment groups with respect to the PRNT60 titers to each patient’s 
autologous serotype. As expected, in many cases the highest plasma titer in each 
patient was not to the serotype responsible for their recent infection. Collectively, 
these results suggest the antibody response to DENV infection is not impaired by 
prednisolone therapy.
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Figure 5-7: Serological responses and prednisolone therapy. Comparisons of A. 
IgM at discharge; B. IgG at discharge (4-lldays post-treatment); and C. PRNT60 
values 6 months after illness. No differences were found between the treatment 
groups
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5.4 Discussion
A host pro-inflammatory immune response is widely believed to contribute to the 
increased capillary permeability associated with dengue infections. Therapeutic 
agents such as corticosteroids might attenuate this host response and thus provide 
clinical benefits. The current study was linked to a randomized controlled trial of 
early prednisolone therapy for dengue and focused on the effect of prednisolone on 
virological factors. The results emphasize the prednisolone safety profile by showing 
that prednisolone did not increase dengue viremia or prolong NS1 antigenemia in 
patient plasma. In addition, the work also provides insight into the poor therapeutic 
efficacy of prednisolone by identifying only a small prednisolone-associated footprint 
(just 81 transcripts differentially abundant from 47,231 evaluated) on the whole-blood 
gene expression profile. Moreover, neither acute-phase plasma cytokine 
concentrations nor the percentage of activated T cells in early convalescence were 
measurably attenuated by prednisolone treatment. The limited immunomodulation 
achieved by prednisolone is consistent with it having negligible measurable benefits 
in the clinical trial on which this work is based.
There is extensive clinical experience of using corticosteroids in the management of 
non-acute, non-infectious inflammatory diseases. Corticosteroids are believed to 
deliver clinical benefits in these inflammatory conditions via genomic and non- 
genomic pharmacological actions that result in inhibition of transcription of pro- 
inflammatory genes and an increase in the transcription of anti-inflammatory genes 
[187]. Corticosteroids also elicit apoptosis in activated human T cells and can 
suppress the virus-induced production of type I IFNs and modulate their downstream 
signaling [188, 189]. Against this backdrop, where the immunomodulatory actions of 
corticosteroids are well established, it was surprising that stronger signals of immune- 
modulation were not observed in this current study. The absence of a measurable 
impact of prednisolone on plasma cytokine concentrations two days after enrolment 
reflects the absence of any significant elevation of the 1 1  investigated cytokines in the 
acute phase compared to convalescence. This is at odds with a body of literature 
indicating elevated plasma/serum cytokine concentrations are a prominent feature in
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the host response [8 8 ]. However one limitation of this work, in comparison to other 
studies is that cytokine/chemokine concentrations were not measured in serial daily 
plasma specimens and therefore may have missed transient changes in particular 
markers [38, 8 6 ].
Although corticosteroids are recognized for their pro-apoptotic effect in leukocytes 
[188, 190], there was no evidence for a prednisolone-associated reduction in CD4+ or 
CD8 + T cells bearing surface activation markers during early convalescence. Since the 
study involved only 1 0 0  consecutive patients, it is plausible it was underpowered to 
detect subtle differences in T cell responses between treatment groups. However, the 
absence of any measurable effect in this sample size suggests the impact of 
prednisolone on the characteristics of the blood T cell population that was 
investigated is not large. In the serology assays the total anti-dengue IgM and IgG 
levels do not differentiate between serotype specific and serotype cross-reactive 
antibodies, which have been reported to be different in their neutralizing abilities 
[191]. However, they still reflect the overall antibody response in dengue, and yet 
there was no apparent effect of prednisolone in this study, with similar levels of 
capture IgG and IgM on the discharge day as well as similar PRNT titers 6  months 
after the onset of the acute illness.
At the transcriptional level, there were changes in the whole-blood host gene 
expression profile in patients that had received 2 mg/kg prednisolone (but not the 
lower dose, 0.5 mg/kg) compared to placebo-treated patients. A striking finding was 
the under-abundance of transcripts representing granzyme B (GZMB), granzyme H 
(GZMH), granulysin (GNLY), perforin (PRF1), Ksp37 (FGFBP2) and cathepsin W 
(CTSW), each of which is associated with the secretory and cytolytic activities of T 
and NK cells. This was independent of the blood lymphocyte count. Furthermore, 
transcripts from eomesodermin (EOMES: a transcriptional regulator required for full 
effector differentiation of CD8 + T cells and NK cells) and SH2D2A which encodes 
TSAd (a positive regulator of proximal T cell receptor signal transduction) were also 
under abundant in prednisolone treated patients [192, 193]. High-dose prednisolone 
treatment was also associated with an under-abundance of transcripts from genes
113
Chapter 5
belonging to the leukocyte associated Ig like receptor 1 (LAIR1) and the killer-cell 
immunoglobulin-like receptor family (KIR3DL1, KIR2DL4). These genes are 
involved in the regulation of NK cell activity to prevent recognition of self, and their 
under-abundance might suggest dysfunction of normal NK cell responses during 
prednisolone therapy. Prednisolone treatment was associated with elevated transcripts 
encoding decoy receptor of interleukin 1 (IL1R2), the endocytic receptor for 
hemoglobin-haptoglobin (CD 163) and orosomucoid 1 (ORM1), all of which are 
known to be corticosteroid induced [194-197]. These proteins are produced by 
neutrophils or monocytes/macrophages and take part in anti-inflammatory reactions. 
Moreover, each has been reported to interfere directly or indirectly with the 
proliferation and cytolytic response of T cells [198-201]. Taken together, the 
diminished abundance of transcripts encoding T and NK effector proteins might 
suggest impaired anti-viral cytolytic responses during high-dose prednisolone therapy. 
However viremia levels were not significantly higher or more prolonged in 
prednisolone-treated patients, nor did these patients have other hematological or 
biochemical laboratory abnormalities that would suggest impaired viral clearance. It 
is plausible that the lower transcript abundance of these elements in whole blood is 
not biologically significant in terms of resolving infection and that other components 
of the immune response, such as antibodies or complement, are more important and/or 
compensatory.
Although quite comprehensive in approach, there are some limitations to the work
presented here. Previously, in vitro studies have shown prednisolone to have a
significant effect on complement activation [202, 203], and in other clinical studies,
prednisolone has been shown to provide benefit in rheumatoid arthritis and lung or
cardiac surgery by inhibiting complement activation [204-207]. In this study, although
I found down regulation of the gene encoding for C1QB in high-dose patients
compared with placebo recipients, I did not find alterations in other components of the
complement system. Unfortunately I was unable to confirm this result by qRT-PCR
due to limited remaining samples. Neither was I able to assess complement activation
although there is good evidence that complement is consumed and split products
generated in the course of dengue, and that this may be important to pathogenesis
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[6 8 ]. Secondly the sampling schedule may have missed transient but important 
differences in cellular gene expression signals between patients in different treatment 
arms. And finally prednisolone may have important actions in tissues that are not 
revealed in whole blood.
Nevertheless these results, coupled with the findings from the clinical trial, suggest 
that early prednisolone therapy has little impact on the host immune response or the 
clinical evolution of dengue. One possible explanation is that early prednisolone 
therapy is “too little, too late” to attenuate the infection-driven processes that lead to 
the altered capillary permeability, thrombocytopenia, and haemostatic derangements. 
Even earlier treatment, or possibly higher dose therapy, might have led to a greater 
prednisolone impact on the immune response and the clinical/laboratory phenotype. 
However, enrolling into this trial was quite challenging (with around one third of 
patients enrolled on day 2, and two thirds enrolled on day 3 of illness), and attempting 
to enroll patients prior to day 2 of illness would be even more difficult. Use of higher 
dose therapy would be problematic since a small number of subjects on the 2 mg/kg 
dose developed hyperglycemia, a well recognized complication of steroid therapy, 
and it is unlikely that clinicians would consider this an acceptable risk to take with a 
treatment eventually intended to be administered to large numbers of patients at the 
community level.
Notwithstanding these limitations, the results described here underscore the challenge 
of modulating an immune response that has been driven by days of DENV replication 
in host tissues. More fundamentally, these results are a reminder that although 
immune-driven pathophysiological changes are good candidates to explain capillary 
permeability, the precise causal mechanisms remain poorly understood. This 
represents a major knowledge gap in our understanding of disease pathogenesis that 
also undermines development of specific therapeutic interventions in the future.
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GENERAL DISCUSSION AND FUTURE POSSIBILITY
This thesis makes several significant steps towards developing a better understanding 
of dengue pathogenesis. First, I established all-inclusive models based on both in- 
house and commercial serological tests to define immune status, a well established 
factor known to influence pathogenesis. Advantages of these models compared to the 
current systems include convenience of sampling (single specimens taken during the 
acute illness) and high accuracy (80 -  85%), as well as the use of relatively simple 
serological techniques. In particular the model based on the Panbio Indirect IgG 
ELISA gave the best performance (accuracy of 85%), and potentially could be widely 
applied in dengue pathogenesis studies, capitalizing on the high reproducibility of this 
commercial kit. To date there has been considerable variability in how immune status 
is defined in pathogenesis studies. Both HI and PRNT, currently regarded as the gold 
standard for defining immune status, are complicated and/or time consuming to 
perform and are not standardized between different laboratories around the world. 
Similarly algorithms based on in-house serological assays vary considerably between 
laboratories. Although use of commercial kits is constrained by their high cost, 
consistency is generally good both between centers and over time.
The all-inclusive model based on the Panbio Indirect IgG performed better in the 
early phase, before Day 5 of illness. For assessing dengue patients during the late 
acute phase, the good performance characteristics of our in-house capture IgG and the 
in-house capture IgM/IgG ratio are encouraging. For more widespread use similar 
algorithms based on commercial capture IgM and IgG kits are likely to perform well 
and should be evaluated formally in a similar way. It would also be valuable to assess 
the generalizability of the models I have developed in other epidemiological settings 
with different endemicity and to include evaluation of the possible effects of other 
flaviviruses.
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From a clinical perspective since secondary dengue is a risk factor for severe disease 
and the all-inclusive model based on Panbio Indirect IgG was able to define immune 
status with high accuracy very early in the course of illness (Day 2) based on a single 
specimen, it is possible the algorithm might also be useful in clinical practice. The test 
would need to be combined with an effective test to also make a definitive diagnosis 
of dengue at this time. Modem PCR techniques are now very sensitive, and both 
formal NS1 ELISAs and NS1 rapid tests can be used for this purpose, albeit with 
certain limitations on sensitivity. Using this kind of combined approach it might be 
possible to decrease the number of patients currently hospitalized for close 
monitoring, thus decreasing the overall burden on healthcare systems where dengue is 
endemic. Similarly it might be possible to use this strategy to target enrolment to 
intervention trials of potential dengue therapeutics to the patient population most at 
risk of developing severe disease.
Second, I confirmed and expanded the current knowledge base regarding the 
influence of immune status and serotype on the magnitude and kinetics of dengue 
viremia, by carrying out detailed assessments on almost 900 patients infected with 
DENV1, DENV2, and DENV3. In our laboratory in-house IgG and IgM capture 
ELISAs are used routinely to process very large numbers of specimens each year; I 
applied the model based on the in-house capture IgM/IgG ratio to define the immune 
status of these patients and measured plasma viremia daily throughout the acute 
illness. I found clear differences in viremia kinetics between the 3 serotypes assessed, 
with viremia typically being highest in DENVI and lowest in DENV3 infections. I 
confirmed the higher viremia associated with primary DENV1 infections compared to 
secondary DENV1 infections that was reported previously by our group, and was also 
able to examine the effect of immune status on viremia in DENV2 and DENV3 
infections. Similar to DENV1 I found higher viremia in primary compared to 
secondary DENV3 infections but I found no difference in viremia between primary 
and secondary DENV2 infections.
The finding of generally higher viremia in DENV1 infections is interesting, 
particularly in view of the fact that DENV1 has been the predominant serotype
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circulating in southern Vietnam for almost a decade from 2006 until now. If DENV1 
has better fitness than other serotypes, resulting in higher viremia, this may offer a 
competitive advantage and potentially alter transmission dynamics since plasma 
viremia is known to influence the likelihood of developing a viable infection in the 
mosquito vectors. The clear differences in viremia patterns between the three 
serotypes are also intriguing. One limitation is that we do not know anything about 
viremia kinetics before the onset of symptoms -  although we enroled the study 
participants early in the illness course viremia was almost always already declining by 
this time. Further work to try to understand the contribution of viremia kinetics and 
immune status in the presymptomatic phase using mathematical modeling may prove 
informative, although many assumptions must be made and there is always 
uncertainty about whether modeling findings really reflect the biological facts. 
Another potential source of information would be from challenge studies using non­
human primates. However relationships between findings in animal models and what 
happens in human disease are also not known, and results from such studies must also 
be interpreted with caution. Human challenge studies using wild-type viruses were 
performed in endemic populations many decades ago, and may be a useful 
methodology to revisit to try to understand dengue pathogenesis, particularly since 
sophisticated modem techniques to assess virological and immunological responses 
could be applied to samples obtained in the presymptomatic phase. However, the 
ethics and safety of such studies needs to be carefully considered, as well as the 
practicalities of performing challenge studies in endemic settings where participants 
may be bitten by infected mosquitoes anyway.
This is the first time an association between higher viremia in the early acute phase
(Day 3) and the risk for subsequent development of DSS has been identified.
Although some previous studies have found associations between viremia and dengue
severity assessed in terms of DF versus DHF, the findings have not been consistent
across studies, probably because sample sizes have generally been small and the
natural evolution of viremia during the illness course has not always been accounted
for. Clear differentiation between DF and DHF is also difficult without very stringent
clinical data collection, while DSS is much more straightforward to identify. The
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findings from this work strongly support viremia as an important factor in 
determining dengue pathogenesis, and reinforce the view that viremia is an important 
endpoint for use in clinical trials of dengue therapeutics. Similarly, as higher viremia 
on Day 3 was associated with progression to dengue shock, this could be considered 
for incorporation into clinically relevant algorithms designed to identify high risk 
patients and influence decision-making about whether to triage a particular individual 
for admission or observation as an outpatient.
In addition to trying to understand dengue pathogenesis, considerable efforts are being
made by the dengue research community to advance strategies to control dengue,
ideally by developing a safe and effective vaccine or by eliminating dengue using
novel vector control methods such as the mosquito parasite, Wolbachia. However
even though these programs may be successful in the long term, effective treatment
for dengue is still required now. A number of anti-viral agents have been trialed and
shown to be safe, but unfortunately to date none of these agents were successful in
reducing plasma viremia or in preventing the development of clinical complications.
Our group recently assessed the safety of an alternative approach, using immune
modulation with oral prednisolone early in the disease course, but also failed to
demonstrate clinical efficacy. The third main area of research presented in this thesis
relates to the work I did for this clinical trial to demonstrate prednisolone’s safety
profile by showing that it did not augment or lengthen the existing plasma viremia or
NS1 antigenaemia. I also investigated the effects of early prednisolone therapy on the
transcriptional profile of a range of immunological correlates, but could only identify
a small prednisolone-associated footprint -  only 81 transcripts were differentially
abundant between the prednisolone and placebo recipients among the 47,231 that I
evaluated. Also there was no significant effect of prednisolone on cytokine levels, T
cell phenotypes or antibody responses. It is possible that these findings reflect the
timing of the prednisolone therapy; even though treatment was commenced within 72
hours of fever onset this may still be too late to alter the trajectory of a disease course
established even before the onset of symptoms. Alternatively the dose of prednisolone
may have been too low to influence the immune response, but since some patients
receiving the higher prednisolone dose in the trial already experienced adverse effects
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it would not be feasible to increase it. Another explanation of the poor effectiveness 
of prednisolone is that the treatment was not directed at the appropriate population. 
Usually, dengue is a relatively mild disease, with most patients recovering 
spontaneously after several days of fever and only a small proportion of cases 
developing severe disease. Prednisolone may have little or no effect on these mild 
patients, and this may have diluted any real prednisolone effect in our trial. If the trial 
could be conducted on patients who were more likely to progress to severe dengue, it 
is possible prednisolone might have shown better effect. However, in order to identify 
such patients a good prognostic algorithm is required, and at present no suitable 
algorithm has been identified. Work is ongoing in a very large multicentre 
observational study to try to develop an effective prognostic algorithm, and it is 
possible that a) inclusion of a method to identify secondaiy dengue cases in the early 
acute phase, and b) measurement of plasma viremia within 72 hours, may both 
contribute to such an algorithm.
Although early prednisolone therapy failed to show efficacy in this trial, the results 
confirm that our understanding of dengue pathogenesis, especially how immune 
responses alter the pathophysiology of disease, in particular the severity of capillary 
permeability, is poor. At present our understanding about dengue immuno- 
pathogenesis is mainly derived from in-vitro studies or studies using animal-models, 
and interpretation of these findings needs careful consideration. Pathogenesis studies 
on humans will become increasingly important if we are to improve our 
understanding of this complex disease.
In summary, in this thesis I have presented the following results from my work 
focused on assessing plasma viremia and host immune responses in dengue, aiming to 
better understand disease pathogenesis:
>  I developed a number of models based on both in-house (capture IgG,
capture IgM/IgG ratio) and commercial (Panbio Indirect IgG) assays that
could differentiate primary from secondary dengue, using single
specimens obtained on any day of illness during the acute phase with high
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accuracy. The model based on the Panbio Indirect IgG could be applied in 
future studies of pathogenesis across a variety of settings, allowing 
comparisons between different laboratories and research groups across the 
world, while the models based on the in-house capture IgG assay and in- 
house capture IgM/IgG ratio are very useful for studies performed locally 
by our group in Ho Chi Minh City.
>  I expanded the current knowledge base regarding the influence of immune 
status and serotype on the magnitude and kinetics of plasma viremia in 
almost 900 patients covering the spectrum of clinical dengue cases seen in 
our setting. Viremia was lower in secondary than primary DENV1 and 
DENV3 infections, but it was not significantly affected by immune status 
in DENV2 infections. Viremia was also generally higher in DENV1 
infections compared to the other serotypes, potentially reflecting better 
fitness of this serotype. Higher viremia on Day 3 of illness was more likely 
to be associated with worse clinical outcomes, including a lower platelet 
nadir, greater haemoconcentration, and development of shock.
> Although early therapy with prednisolone did not have a demonstrable 
clinical effect on patient outcomes in our recent clinical trial, its use during 
the phase of active viral replication was shown to be safe by demonstrating 
that the drug did not lengthen or increase plasma viremia or NS1 
antigenaemia. In addition, there was a rather limited effect of prednisolone 
on the whole blood transcriptional profile and on immune responses 
(cytokine levels, T cell phenotypes and antibody responses), in agreement 
with the lack of a measurable clinical benefit in the trial.
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